US20090061454A1 - Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells - Google Patents

Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells Download PDF

Info

Publication number
US20090061454A1
US20090061454A1 US12/282,320 US28232007A US2009061454A1 US 20090061454 A1 US20090061454 A1 US 20090061454A1 US 28232007 A US28232007 A US 28232007A US 2009061454 A1 US2009061454 A1 US 2009061454A1
Authority
US
United States
Prior art keywords
genes
group
unigene
expression
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/282,320
Other languages
English (en)
Inventor
Jerome S. Brody
Avrum Spira
Jeffrey S. Berman
Anthony W. O'Regan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US12/282,320 priority Critical patent/US20090061454A1/en
Assigned to THE TRUSTEES OF BOSTON UNIVERSITY reassignment THE TRUSTEES OF BOSTON UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SPIRA, AVRUM, BERMAN, JEFFREY S, BRODY, JEROME S, O'REGAN, ANTHONY W
Publication of US20090061454A1 publication Critical patent/US20090061454A1/en
Assigned to GALA THERAPEUTICS BVBA - SPRL reassignment GALA THERAPEUTICS BVBA - SPRL SECURITY AGREEMENT Assignors: ALLEGRO DIAGNOSTICS CORP.
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: BOSTON UNIVERSITY MEDICAL CAMPUS
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • the present invention is directed to methods for diagnosing lung diseases from nasal epithelial cells using gene expression analysis. More specifically, the invention is directed to diagnostic and prognostic methods for detecting from nasal epithelial cell samples lung diseases, particularly lung cancer in subjects, preferably humans. The invention also provides genes the expression of which can be used to analyze lung diseases from the nasal epithelial cell samples.
  • Lung disorders represent a serious health problem in the modern society. For example, lung cancer claims more than 150,000 lives every year in the United States, exceeding the combined mortality from breast, prostate and colorectal cancers. Cigarette smoking is the most predominant cause of lung cancer. Presently, 25% of the U.S. population smokes, but only 10% to 15% of heavy smokers develop lung cancer. There are also other disorders associated with smoking such as emphysema. There are also health questions arising from people exposed to smokers, for example, second hand smoke. Former smokers remain at risk for developing such disorders including cancer and now constitute a large reservoir of new lung cancer cases. In addition to cigarette smoke, exposure to other air pollutants such as asbestos, and smog, pose a serious lung disease risk to individuals who have been exposed to such pollutants.
  • other air pollutants such as asbestos, and smog
  • the methods that are currently employed to diagnose lung cancer include chest X-ray analysis, bronchoscopy or sputum cytological analysis, computer tomographic analysis of the chest, and positron electron tomographic (PET) analysis.
  • chest X-ray analysis e.g., chest X-ray analysis
  • bronchoscopy or sputum cytological analysis e.g., computer tomographic analysis of the chest
  • PET positron electron tomographic
  • the method of sampling epithelial cells from bronchial tissue while less invasive than many other methods has some drawbacks.
  • the patient may not eat or drink for about 6-12 hours prior to the test.
  • the procedure is performed using a rigid bronchoscope the patient needs general anesthesia involving related risks to the patient.
  • the procedure is performed using a flexible bronchoscope, the procedure is performed using local anesthesia.
  • uncomfortable sensations such as a sensation of suffocating during such a procedure and thus are relatively resistant for going through the procedure more than once.
  • the throat may feel uncomfortably scratchy for several days.
  • RNA can be isolated from mouth epithelial cells for gene expression analysis (U.S. Ser. No. 10/579,376), it has not been clear if such samples routinely reflect the same gene expression changes as bronchial samples that can be used in accurate diagnostic and prognostic methods.
  • the present invention provides a much less invasive method for diagnosing lung diseases, such as lung cancer based on analysis of gene expression in nose epithelial cells.
  • the invention provides methods for diagnosis, prognosis and follow up of progression or success of treatment for lung diseases using gene expression analysis from nose epithelial cells.
  • the method provides an optimal means for screening for changes indicating malignancies in individuals who, for example are at risk of developing lung diseases, particularly lung cancers because they have been exposed to pollutants, such as cigarette or cigar smoke or asbestos or any other known pollutant.
  • the method allows screening at a routine annual medical examination because it does not need to be performed by an expert trained in bronchoscopy and it does not require sophisticated equipment needed for bronchoscopy.
  • the gene expression analysis can be performed using genes and/or groups of genes as described in tables 8, 9 and 10 and, for example, in PCT/US2006/014132. Naturally, other diagnostic genes may also be used, as they are identified.
  • the invention provides a substantially less invasive method for diagnosis, prognosis, and follow-up of lung diseases using samples from nasal epithelial cells.
  • one preferably uses gene expression analysis.
  • the analysis and discoveries presented herein allow us to conclude that those gene expression changes can also be analyzed from nasal epithelial cells thus providing a much less invasive and more accurate method for diagnosing lung diseases in general.
  • any lung disease that results in detectable gene expression changes including, but not limited to acute pulmonary eosinophilia (Loeffler's syndrome), CMV pneumonia, chronic pulmonary coccidioidomycosis, cryptococcosis, disseminated tuberculosis (infectious), chronic pulmonary histoplasmosis, pulmonary actinomycosis, pulmonary aspergilloma (mycetoma), pulmonary aspergillosis (invasive type), pulmonary histiocytosis X (eosinophilic granuloma), pulmonary nocardiosis, pulmonary tuberculosis, and sarcoidosis.
  • acute pulmonary eosinophilia Lieffler's syndrome
  • CMV pneumonia chronic pulmonary coccidioidomycosis
  • cryptococcosis disseminated tuberculosis (infectious)
  • chronic pulmonary histoplasmosis pulmonary acti
  • Our preferred groups are the groups of 361 (Table 8), 107 (Table 9), 70 (Table 10), 96 (Table 1), 84 (Table 2), 50 (Table 3), 36 (Table 4), 80 (Table 5), 535 (Table 6) and 20 (Table 7).
  • control groups can be individuals who have not been exposed to a particular airway irritant, such as non-smokers, smokers, or former smokers, or individuals not exposed to viruses or other substance that can cause a “filed effect” in the airways thus resulting in potential for lung disease.
  • the control sample should be from an individual who does not have the diseases and alternatively include one or more samples with individuals who have similar or different lung diseases.
  • comparing can be performed in the biological sample from a smoker against a control group of smokers who do not have lung cancer.
  • the transcripts or expression products against the control for increased expression or decreased expression, which depends upon the particular gene and is set forth in the tables—not all the genes surveyed will show an increase or decrease. However, at least 50% of the genes surveyed must provide the described pattern.
  • the nasal epithelial cell sample is analyzed for a group of genes the expression of which is altered in individuals who are at risk of developing lung diseases, such as lung cancer, because of the exposure to air pollutants or other airway irritant such as microbes that occur in the air and are inhaled.
  • lung diseases such as lung cancer
  • air pollutant air pollutant
  • the method can also be used for analysis of groups of genes the expression of which is consistently altered as a group in individuals who are at risk of developing lung diseases because of the exposure to such air pollutants including microbes and viruses present in the air.
  • the invention provides a method of diagnosing a lung disease such as lung cancer using a combination of nasal epithelial cells and the analysis of gene expression pattern of the gene groups as described in the present invention.
  • the invention provides methods for analyzing gene groups from nasal epithelial cells, wherein the gene expression pattern that can be directly used in diagnosis and prognosis of lung diseases.
  • the invention provides analysis from nasal epithelial cells groups of genes the expression profile of which provides a diagnostic and or prognostic test to determine lung disease in an individual exposed to air pollutants.
  • the invention provides analysis from nasal epithelial cells, groups of genes the expression profile of which can distinguish individuals with lung cancer from individuals without lung cancer.
  • the invention provides an early asymptomatic screening system for lung cancer by using the analysis of nasal epithelial cells for the disclosed gene expression profiles. Such screening can be performed, for example, in similar age groups as colonoscopy for screening colon cancer. Because early detection in lung cancer is crucial for efficient treatment, the gene expression analysis system of the present invention provides an improved method to detect tumor cells. Thus, the analysis can be made at various time intervals, such as once a year, once every other year for screening purposes. Alternatively, one can use a more frequent sampling if one wishes to monitor disease progression or regression in response to a therapeutic intervention. For example, one can take samples from the same patient once a week, once or two times a month, every 3, 4, 5, or 6 months.
  • the probes that can be used to measure expression of the gene groups of the invention can be nucleic acid probes capable of hybridizing to the individual gene/transcript sequences identified in the present invention, or antibodies targeting the proteins encoded by the individual gene group gene products of the invention.
  • the probes are preferably immobilized on a surface, such as a gene or protein chip so as to allow diagnosis and prognosis of lung diseases in an individual.
  • the invention provides a group of genes that can be used in diagnosis of lung diseases from the nasal epithelial cells. These genes were identified using
  • the invention provides a group of genes that can be used as individual predictors of lung disease. These genes were identified using probabilities with a t-test analysis and show differential expression in smokers as opposed to non-smokers.
  • the group of genes comprise ranging from 1 to 96, and all combinations in between, for example 5, 10, 15, 20, 25, 30, for example at least 36, at least about, 40, 45, 50, 60, 70, 80, 90, or 96 gene transcripts, selected from the group consisting of genes identified by the following GenBank sequence identification numbers (the identification numbers for each gene are separated by “;” while the alternative GenBank ID numbers are separated by “///”): NM — 003335; NM — 000918; NM — 006430.1; NM — 001416.1; NM — 004090; NM — 006406.1; NM — 003001.2; NM — 001319; NM — 006545.1; NM — 021145.1; NM —
  • the gene/transcript analysis comprises a group of about 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80, 80-90, 90-100, 100-120, 120-140, 140-150, 150-160, 160-170, 170-180, 180-190, 190-200, 200-210, 210-220, 220-230, 230-240, 240-250, 250-260, 260-270, 270-280, 280-290, 290-300, 300-310, 310-320, 320-330, 330-340, 340-350, 350-360, 360-370, 370-380, 380-390, 390-400, 400-410, 410-420, 420-430, 430-440, 440-450, 450-460, 460-470, 470-480, 480-490, 490-500, 500-510, 510-520, 520-530, and up to about 535 genes selected from the group consisting of genes or transcripts
  • the genes are selected from the group consisting of genes or transcripts as shown in Table 5.
  • the genes are selected from the genes or transcripts as shown in Table 7.
  • the transcript analysis gene group comprises a group of individual genes the change of expression of which is predictive of a lung disease either alone or as a group, the gene transcripts selected from the group consisting of NM — 007062.1; NM — 001281.1; BC002642.1; NM — 000346.1; NM — 006545.1; BG034328; NM — 019067.1; NM — 017925.1; NM — 017932.1; NM — 030757.1; NM — 030972.1; NM — 002268///NM — 032771; NM — 007048///NM — 194441; NM — 006694; U85430.1; NM — 004691; AB014576.1; BF218804; BE467941; R83000; AL161952.1; AK023843.1; AK021571.1; AK023783.1; AL080112.1;
  • the gene group comprises a probe set capable of specifically hybridizing to at least all of the 36 gene products.
  • Gene product can be mRNA which can be recognized by an oligonucleotide or modified oligonucleotide probe, or protein, in which case the probe can be, for example an antibody specific to that protein or an antigenic epitope of the protein.
  • the invention provides a gene group, wherein the expression pattern of the group of genes provides diagnostic for a lung disease.
  • the gene group comprises gene transcripts encoded by a gene group consisting of at least for example 5, 10, 15, 20, 25, 30, preferably at least 36, still more preferably 40, still more preferably 45, and still more preferably 46, 47, 48, 49, or all 50 of the genes selected from the group consisting of and identified by their GenBank identification numbers: NM — 007062.1; NM — 001281.1; BC000120.1; NM — 014255.1; BC002642.1; NM — 000346.1; NM — 006545.1; BG034328; NM — 021822.1; NM — 021069.1; NM — 019067.1; NM — 017925.1; NM — 017932.1; NM — 030757.1; NM — 030972.1; AF126181.1; U 93240.1; U90552.1;
  • the invention provides a group of about 30-180, preferably, a group of about 36-150 genes, still more preferably a group of about 36-100, and still more preferably a group of about 36-50 genes, the expression profile of which is diagnostic of lung cancer in individuals who smoke.
  • the invention provides a group of genes the expression of which is decreased in an individual having lung cancer.
  • the group of genes comprises at least 5-10, 10-15, 15-20, 20-25 genes selected from the group consisting of NM — 000918; NM — 006430.1; NM — 001416.1; NM — 004090; NM — 006406.1; NM — 003001.2; NM — 006545.1; NM — 002437.1-NM — 006286; NM — 001123///NM — 006721; NM — 024824; NM — 004935.1; NM — 001696; NM — 005494///NM — 058246; NM — 006368; NM — 002268///NM — 032771; NM — 006694; NM — 004691; NM — 012394; NM —
  • the group of genes comprises genes selected from the group consisting of NM — 014182.1; NM — 001281.1; NM — 024006.1; AF135421.1; L76200.1; NM — 000346.1; BC008710.1; BC000423.2; BC008710.1; NM — 007062; BC075839.1///BC073760.1; BC072436.1///BC004560.2; BC001016.2; BC005023.1; BC000360.2; BC007455.2; BC023528.2///BC047680.1; BC064957.1; BC008710.1; BC066329.1; BC023976.2; BC008591.2///BC050440.1///BC048096.1; and BC028912.1.
  • the group of genes comprises genes selected from the group consisting of NM — 007062.1; NM — 001281.1; BC000120.1; NM — 014255.1; BC002642.1; NM — 000346.1, NM — 006545.1; BG034328; NM — 021822.1; NM — 021069.1; NM — 019067.1; NM — 017925.1; NM — 017932.1; NM — 030757.1; NM — 030972.1; AF126181.1; U93240.1; U90552.1; AF151056.1; U85430.1; U51007.1; BC005969.1; NM — 002271.1; AL566172; and AB014576.1.
  • the invention provides a group of genes the expression of which is increased in an individual having lung cancer.
  • the group of genes comprises genes selected from the group consisting of NM — 003335; NM — 001319; NM — 021145.1; NM — 001003698///NM — 001003699///; NM — 002955; NM — 002853.1; NM — 019067.1; NM — 024917.1; NM — 020979.1; NM — 005597.1; NM — 007031.1; NM — 009590.1; NM — 020217.1; NM — 025026.1; NM — 014709.1; NM — 014896.1; AF010144; NM — 005374.1; NM — 006534///NM — 81659; NM — 014033; NM — 016138;
  • the group of genes comprises genes selected from the group consisting of NM — 030757.1; R83000; AK021571.1; NM — 17932.1; U85430.1; AI683552; BC002642.1; AW024467; NM — 030972.1; BC021135.1; AL161952.1; AK026565.1; AK023783.1; BF218804; AK023843.1; BC001602.1; BC034707.1; BC064619.1; AY280502.1; BC059387.1; BC061522.1; U50532.1; BC006547.2; BC008797.2; BC000807.1; AL080112.1; BC033718.1///BC046176.1///; BC038443.1; Hs.288575 (UNIGENE ID); AF020591.1; BC002503.2; BC009185.2; Hs.528304 (UNIGENE ID); U50532.1; BC013923.2; BC031091
  • the group of genes comprises genes selected from the group consisting of BF218804; AK022494.1; AA114843; BE467941; NM — 003541.1; R83000; AL161952.1; AK023843.1; AK021571.1; AK023783.1; AU147182; AL080112.1; AW971983; AI1683552; NM — 024006.1; AK026565.1; NM — 014182.1; NM — 021800.1; NM — 016049.1; NM — 019023.1; NM — 021971.1; NM — 014128.1; AK025651.1; AA133341; and AF198444.1.
  • the invention provides a method for diagnosing a lung disease comprising obtaining a nucleic acid sample from lung, airways or mouth of an individual exposed to an air pollutant, analyzing the gene transcript levels of one or more gene groups provided by the present invention in the sample, and comparing the expression pattern of the gene group in the sample to an expression pattern of the same gene group in an individual, who is exposed to similar air pollutant but not having lung disease, such as lung cancer or emphysema, wherein the difference in the expression pattern is indicative of the test individual having or being at high risk of developing a lung disease.
  • the decreased expression of one or more of the genes is indicative of the person having a lung disease or being at high risk of developing a lung disease, preferably lung cancer, in the near future and needing frequent follow ups to allow early treatment of the disease.
  • the lung disease is lung cancer.
  • the air pollutant is tobacco or tobacco smoke.
  • the diagnosis can separate the individuals, such as smokers, who are at lesser risk of developing lung diseases, such as lung cancer by analyzing from the nasal epithelial cells the expression pattern of the gene groups of the invention provides a method of excluding individuals from invasive and frequent follow ups.
  • the invention provides methods for prognosis, diagnosis and therapy designs for lung diseases comprising obtaining an nasal epithelial cell sample from an individual who smokes and analyzing expression profile of the gene groups of the present invention, wherein an expression pattern of the gene group that deviates from that in a healthy age, race, and gender matched smoker, is indicative of an increased risk of developing a lung disease.
  • Tables 1-4 indicate the expression pattern differences as either being down or up as compared to a control, which is an individual exposed to similar airway pollutant but not affected with a lung disease.
  • the invention also provides methods for prognosis, diagnosis and therapy designs for lung diseases comprising obtaining an nasal epithelial cell sample from a non-smoker individual and analyzing expression profile of the gene groups of the present invention, wherein an expression pattern of the gene group that deviates from that in a healthy age, race, and gender matched smoker, is indicative of an increased risk of developing a lung disease.
  • the analysis is performed using nucleic acids, preferably RNA, in the biological sample.
  • the analysis is performed analyzing the amount of proteins encoded by the genes of the gene groups of the invention present in the sample.
  • the analysis is performed using DNA by analyzing the gene expression regulatory regions of the groups of genes of the present invention using nucleic acid polymorphisms, such as single nucleic acid polymorphisms or SNPs, wherein polymorphisms known to be associated with increased or decreased expression are used to indicate increased or decreased gene expression in the individual. For example, methylation patterns of the regulatory regions of these genes can be analyzed.
  • the present invention provides a minimally invasive sample procurement method for obtaining nasal epithelial cell RNA that can be analyzed by expression profiling of the groups of genes, for example, by array-based gene expression profiling.
  • expression profiling of the groups of genes for example, by array-based gene expression profiling.
  • array-based gene expression profiling can be used to diagnose individuals who are already affected with a lung disease, such as lung cancer, or who are at high risk of developing lung disease, such as lung cancer, as a consequence of being exposed to air pollutants.
  • These methods can also be used to identify further patterns of gene expression that are diagnostic of lung disorders/diseases, for example, cancer or emphysema, and to identify subjects at risk for developing lung disorders.
  • the invention further provides a method of analyzing nasal epithelial cells using gene group microarray consisting of one or more of the gene groups provided by the invention, specifically intended for the diagnosis or prediction of lung disorders or determining susceptibility of an individual to lung disorders.
  • the invention relates to a method of diagnosing a disease or disorder of the lung comprising obtaining a sample from nasal epithelial cells, wherein the sample is a nucleic acid or protein sample, from an individual to be diagnosed; and determining the expression of group of identified genes in said sample, wherein changed expression of such gene compared to the expression pattern of the same gene in a healthy individual with similar life style and environment is indicative of the individual having a disease of the lung.
  • the invention relates to a method of diagnosing a disease or disorder of the lung comprising obtaining at least two nasal epithelial samples, wherein the samples are either nucleic acid or protein samples, in at least one, two, 3, 4, 5, 6, 7, 8, 9, or more time intervals from an individual to be diagnosed; and determining the expression of the group of identified genes in said sample, wherein changed expression of at least about for example 5, 10, 15, 20, 25, 30, preferably at least about 36, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, or 180 of such genes in the sample taken later in time compared to the sample taken earlier in time is diagnostic of a lung disease.
  • the disease of the lung is selected from the group consisting of asthma, chronic bronchitis, emphysema, primary pulmonary hypertension, acute respiratory distress syndrome, hypersensitivity pneumonitis, eosinophilic pneumonia, persistent fungal infection, pulmonary fibrosis, systemic sclerosis, idiopathic pulmonary hemosiderosis, pulmonary alveolar proteinosis, and lung cancer, such as adenocarcinoma, squamous cell carcinoma, small cell carcinoma, large cell carcinoma, and benign neoplasm of the lung (e.g., bronchial adenomas and hamartomas).
  • asthma chronic bronchitis
  • emphysema primary pulmonary hypertension
  • acute respiratory distress syndrome hypersensitivity pneumonitis
  • eosinophilic pneumonia persistent fungal infection
  • pulmonary fibrosis systemic sclerosis
  • idiopathic pulmonary hemosiderosis pulmonary alveolar proteinosis
  • lung cancer such as a
  • the nucleic acid sample is RNA.
  • individual to be diagnosed is an individual who has been exposed to tobacco smoke, an individual who has smoked, or an individual who currently smokes.
  • the invention also provides analysis of nasal epithelial cells using an array, for example, a microarray for diagnosis of a disease of the lung having immobilized thereon a plurality of oligonucleotides which hybridize specifically to genes of the gene groups which are differentially expressed in airways exposed to air pollutants, such as cigarette smoke, and have or are at high risk of developing lung disease, as compared to those individuals who are exposed to similar air pollutants and airways which are not exposed to such pollutants.
  • the oligonucleotides hybridize specifically to one allelic form of one or more genes which are differentially expressed for a disease of the lung.
  • the differentially expressed genes are selected from the group consisting of the genes shown in tables 1-4; preferably the group of genes comprises genes selected from the Table 3. In one preferred embodiment, the group of genes comprises the group of at least 20 genes selected from Table 3 and additional 5-10 genes selected from Tables 1 and 2. In one preferred embodiment, at least about 10 genes are selected from Table 4.
  • FIG. 1 shows hierarchical clustering of bronchial airway epithelial samples from current (striped box) and never (white box) smokers according to the expression of 60 genes whose expression levels are altered by smoking in the nasal epithelium. Airway samples tend to group with their appropriate class. Dark grey indicates higher level of expression and light grey lower level of expression.
  • FIG. 3 shows smoking related genes in mouth, nose and bronchus.
  • Principal component analysis shows the variation in expression of genes affected by tobacco exposure in current smokers (dark grey) and never smokers (black).
  • Airway epithelium type is indicated by the symbol shape: bronchial (circle), nasal (triangle) and mouth (square). Samples largely separate by smoking status across the first principal component, with the exception of samples from mouth. This indicates a common gene expression host response that can be seen both in the bronchial epithelial tissue and the nasal epithelial tissue.
  • FIG. 4 shows a supervised hierarchical clustering analysis of cancer samples. Individuals with sarcoidosis and individuals with no sarcoids were sampled from both lung tissues and nasal tissues. Gene expression analysis showed that expression of 37 genes can be used to differentiate the cancer samples and non-cancer sampled either from bronchial or nasal epithelial cells. Light grey in the clustering analysis indicates low level of expression and dark grey high level of expression. Asterisk next to the circles indicates that these samples were from an individual with stage 0-1 sarcoidosis. The dot next to the circle indicates that these samples were from an individual with a stage 4 sarcoidosis.
  • FIG. 5 shows airway t-test genes projected on nose data including the 107 leading edge genes as shown in Table 9. Enrichment of differentially expressed bronchial epithelial genes among genes highly changed in the nasal epithelium in response to smoking. Results from GSEA analysis shows the leading edge of the set of 361 differentially expressed bronchial epithelial genes being overrepresented among the top ranked list of genes differentially expressed in nasal epithelium cells in response to smoking. There are 107 genes that comprise the “leading edge subset” (p ⁇ 0.001).
  • FIG. 6 shows 107 Leading Edge Genes from Airway—PCA on Nose Samples. Asterisk next to the circle indicates current smokers. Dark circles represent samples from never smokers. Principal component analysis of 107 “leading edge” genes from bronchial epithelial cells enriched in the nasal epithelial gene expression profile. Two dimensional PCA of the 107 “leading edge” genes from the bronchial epithelial signature that are enriched in the nasal epithelial cell expression profile.
  • FIG. 7 shows a Bronch projection from 10 tissues. From this figure one can see, that the samples from bronchial epithelial cells (dotted squares) and the samples from nose epithelial cells (crossed squares) overlapped closely and were clearly distinct from samples from other tissues, including mouth. Principal component analysis of 2382 genes from normal airway transcriptome across 10 tissues. Principal component analysis (PCA) of 2382 genes from the normal airway transcriptome across 10 different tissue types. Samples separate based on expression of transcriptome genes.
  • PCA Principal component analysis
  • FIG. 8 shows a hierarchical clustering of 51 genes across epithelial cell functional categories.
  • the present invention describes a novel method for prognosis and diagnosis and follow-up for lung diseases.
  • the method is based on detecting gene expression changes of nose epithelial cells which we have discovered closely mirror the gene expression changes in the lung.
  • the invention provides a substantially less invasive method for diagnosis, prognosis and follow-up of lung diseases using gene expression analysis of samples from nasal epithelial cells.
  • nasal brushing For example, one can collect the nasal epithelial cells by brushing the inferior turbinate and/or the adjacent lateral nasal wall.
  • a CYROBRUSH® MedScand Medical, Malmö, Sweden
  • the brush is turned a couple of times, for example 1, 2, 3, 4, 5 times, to collect epithelial cells.
  • the cells can be placed immediately into a solution that prevents nucleic acids from degradation.
  • a solution that prevents nucleic acids from degradation For example, if the cells are collected using the CYTOBRUSH, and one wishes to isolate RNA, the brush is placed immediately into an RNA stabilizer solution, such as RNALATER®, AMBION®, Inc.
  • PBS phosphate buffered saline
  • nucleic acids are then subjected to gene expression analysis.
  • the nucleic acids are isolated and purified.
  • cells may be placed into such device as whole cells without substantial purification.
  • one analyzes gene expression from nasal epithelial cells using gene/transcript groups and methods of using the expression profile of these gene/transcript groups in diagnosis and prognosis of lung diseases.
  • the method provided herein not only significantly increases the diagnostic accuracy of lung diseases, such as lung cancer, but also make the analysis much less invasive and thus much easier for the patients and doctors to perform.
  • lung diseases such as lung cancer
  • the diagnosis of lung cancer is dramatically better by detecting the cancer in an earlier stage than any other available method to date, and by providing far fewer false negatives and/or false positives than any other available method.
  • the invention provides a group of genes useful for lung disease diagnosis from a nasal epithelial cell sample as listed in Tables 8, 9, and/or 10.
  • the invention provides genes
  • Table 6 One example of the gene transcript groups useful in the diagnostic/prognostic tests of the invention is set forth in Table 6. We have found that taking any group that has at least 20 of the Table 6 genes provides a much greater diagnostic capability than chance alone and that these changes are substantially the same in the nasal epithelial cells than they are in the bronchial samples as described in PCT/US2006/014132.
  • Our preferred groups are the groups of 96 (Table 1), 84 (Table 2), 50 (Table 3), 36 (Table 4), 80 (Table 5), 535 (Table 6) and 20 (Table 7). In some instances, we have found that one can enhance the accuracy of the diagnosis by adding additional genes to any of these specific groups.
  • any one or more genes and or transcripts from Table 7 may be added as a lung cancer marker for a gene expression analysis.
  • the genes in the group are compared to a control or a control group.
  • the control groups can be non-smokers, smokers, or former smokers.
  • comparing can be performed in the nasal epithelial cell sample from a smoker against a control group of smokers who do not have lung cancer.
  • At least 50% of the genes surveyed must provide the described pattern. Greater reliability if obtained as the percent approaches 100%.
  • the presently described gene expression profile can also be used to screen for individuals who are susceptible for lung cancer.
  • a smoker who is over a certain age, for example over 40 years old, or a smoker who has smoked, for example, a certain number of years, may wish to be screened for lung cancer.
  • the gene expression analysis from nasal epithelial cells as described herein can provide an accurate very early diagnosis for lung cancer. This is particularly useful in diagnosis of lung cancer, because the earlier the cancer is detected, the better the survival rate is.
  • the group of 80 genes as presented in Table 5 are part of the most frequently chosen genes across 1000 statistical test runs (see Examples below for more details regarding the statistical testing).
  • the 535 genes of Table 6 in our data show up more than 67 times out of 1000.
  • All the 80 genes in Table 5 form a subset of the 535 genes.
  • Table 7 shows the top 20 genes which are subset of the 535 list. The direction of change in expression is shown using signal to noise ratio.
  • a negative number in Tables 5, 6, and 7 means that expression of this gene or transcript is up in lung cancer samples. Positive number in Table 5, 6, and 7, indicates that the expression of this gene or transcript is down in lung cancer.
  • any combination of the genes and/or transcripts of Table 6 can be used.
  • Table 7 provides 20 of the most frequently variably expressed genes in lung cancer when compared to samples without cancer. Accordingly, in one embodiment, any combination of about 3-5, 5-10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or all 20 genes and/or transcripts of Table 7, or any sub-combination thereof are used.
  • the invention provides a gene group the expression profile of nasal epithelial cells which is useful in diagnosing lung diseases and which comprises probes that hybridize ranging from 1 to 96 and all combinations in between for example 5, 10, 15, 20, 25, 30, 35, at least about 36, at least to 40, at lest to 50, at least to 60, to at least 70, to at least 80, to at least 90, or all of the following 96 gene sequences: NM — 003335; NM — 000918; NM — 006430.1; NM — 001416.1; NM — 004090; NM — 006406.1; NM — 003001.2; NM — 001319; NM — 006545.1; NM — 021145.1; NM — 002437.1; NM — 006286; NM — 001003698//NM — 001003699///NM — 002955; NM — 001123///NM
  • the invention provides a gene group the expression profile of nasal epithelial cells of which is useful in diagnosing lung diseases and comprises probes that hybridize to at least, for example, 5, 10, 15, 20, 25, 30, 35, at least about 36, at least to 40, at least to 50, at least to 60, to at least 70, to at least 80, to all of the following 84 gene sequences: NM — 030757.1; R83000; AK021571.1; NM — 014182.1; NM — 17932.1; U85430.1; AI683552; BC002642.1; AW024467; NM — 030972.1; BC021135.1; AL161952.1; AK026565.1; AK023783.1; BF218804; NM — 0012811; NM — 024006.1; AK023843.1; BC001602.1; BC034707.1; BC064619.1; AY280502.1; BC059387.1; AF135421.1; BC061522.1
  • the invention provides a gene group the expression profile of nasal epithelial cells which is useful in diagnosing lung diseases and comprises probes that hybridize to at least, for example 5, 10, 15, 20, 25, 30, preferably at least about 36, still more preferably at least to 40, still more preferably at lest to 45, still more preferably all of the following 50 gene sequences, although it can include any and all members, for example, 20, 21, 22, up to and including 36: NM — 007062.1; NM — 001281.1; BC000120.1; NM — 014255.1; BC002642.1; NM — 000346.1; NM — 006545.1; BG034328; NM — 021822.1; NM — 021069.1; NM — 019067.1; NM — 017925.1; NM — 017932.1; NM — 030757.1; NM — 030972.1; AF126181.1; U93240.1; U90552.1; AF15105
  • the invention provides a gene group the expression profile of nasal epithelial cells which is useful in diagnosing lung diseases and comprises probes that hybridize to at least for example 5, 10, 15, 20, preferably at least about 25, still more preferably at least to 30, still more preferably all of the following 36 gene sequences: NM — 007062.1; NM — 001281.1; BC002642.1; NM — 000346.1; NM — 006545.1; BG034328; NM — 019067.1; NM — 017925.1; NM — 017932.1; NM — 030757.1; NM — 030972.1; NM — 002268///NM — 032771; NM — 007048///NM — 194441; NM — 006694; U85430.1; NM — 004691; AB014576.1; BF218804; BE467941; R83000; AL161952.1; AK0
  • a probe set useful in the methods of the present invention is selected from the nucleic acid probes of between 10-15, 15-20, 20-180, preferably between 30-180, still more preferably between 36-96, still more preferably between 36-84, still more preferably between 36-50 probes, included in the Affymetrix Inc.
  • Sequences for the Affymetrix probes are available from Affymetrix. Other probes and sequences that recognize the genes of interest can be easily prepared using, e.g. synthetic oligonucleotides recombinant oligonucleotides. These sequences can be selected from any, preferably unique part of the gene based on the sequence information publicly available for the genes that are indicated by their HUGO ID, GenBank No. or Unigene No.
  • diseases caused by exposure to air pollutants such as cigarette smoke, asbestos or any other pollutant.
  • the analysis can be performed as follows.
  • samples of non-smokers and smokers, non-asbestos exposed individuals and asbestos-exposed individuals, non-smog exposed individuals and smog-exposed individuals, smokers without a lung disease and smokers with lung disease to obtain the differentially expressed gene groups between individuals with no lung disease and individuals with lung disease.
  • the obtained expression analysis such as microarray or microbead raw data consists of signal strength and detection p-value.
  • One normalizes or scales the data, and filters the poor quality chips/bead sets based on images of the expression data, control probes, and histograms.
  • One filters contaminated specimens which contain non-epithelial cells.
  • one filters the genes of importance using detection p-value.
  • This results in identification of transcripts present in normal airways (normal airway transcriptome). Variability and multiple regression analysis can be used. This also results in identification of effects of smoking on airway epithelial cell transcription.
  • T-test and Pearson correlation analysis One can also identify a group or a set of transcripts that are differentially expressed in samples with lung disease, such as lung cancer and samples without cancer. This analysis was performed using class prediction models.
  • a weighted voting method For analysis of the data, one can use, for example, a weighted voting method.
  • Committees of variable sizes of the top ranked genes are used to evaluate test samples, but genes with more significant p-values can be more heavily weighed.
  • the accuracy can be validated using cross-valid
  • Table 1 shows 96 genes that were identified as a group distinguishing smokers with cancer from smokers without cancer. The difference in expression is indicated at the column on the right as either “down”, which indicates that the expression of that particular transcript was lower in smokers with cancer than in smokers without cancer, and “up”, which indicates that the expression of that particular transcript was higher in smokers with cancer than smokers without cancer.
  • the exemplary probes shown in the column “Affymetrix Id in the Human Genome U133 chip” can be used.
  • Table 2 shows one preferred 84 gene group that has been identified as a group distinguishing smokers with cancer from smokers without cancer. The difference in expression is indicated at the column on the right as either “down”, which indicates that the expression of that particular transcript was lower in smokers with cancer than in smokers without cancer, and “up”, which indicates that the expression of that particular transcript was higher in smokers with cancer than smokers without cancer.
  • the exemplary probes shown in the column “Affymetrix Id in the Human Genome U133 chip” can be used in the expression analysis.
  • Table 3 shows one preferred 50 gene group that was identified as a group distinguishing smokers with cancer from smokers without cancer. The difference in expression is indicated at the column on the right as either “down”, which indicates that the expression of that particular transcript was lower in smokers with cancer than in smokers without cancer, and “up”, which indicates that the expression of that particular transcript was higher in smokers with cancer than smokers without cancer.
  • This gene group was identified using the GenePattern server from the Broad Institute, which includes the Weighted Voting algorithm. The default settings, i.e., the signal to noise ratio and no gene filtering, were used.
  • the exemplary probes shown in the column “Affymetrix Id in the Human Genome U133 chip” can be used in the expression analysis.
  • Table 4 shows one preferred 36 gene group that was identified as a group distinguishing smokers with cancer from smokers without cancer. The difference in expression is indicated at the column on the right as either “down”, which indicates that the expression of that particular transcript was lower in smokers with cancer than in smokers without cancer, and “up”, which indicates that the expression of that particular transcript was higher in smokers with cancer than smokers without cancer.
  • the exemplary probes shown in the column “Affymetrix Id in the Human Genome U133 chip” can be used in the expression analysis.
  • the gene group of the present invention comprises at least, for example, 5, 10, 15, 20, 25, 30, more preferably at least 36, still more preferably at least about 40, still more preferably at least about 50, still more preferably at least about 60, still more preferably at least about 70, still more preferably at least about 80, still more preferably at least about 86, still more preferably at least about 90, still more preferably at least about 96 of the genes as shown in Tables 1-4.
  • the gene group comprises 36-180 genes selected from the group consisting of the genes listed in Tables 1-4.
  • the invention provides group of genes the expression of which is lower in individuals with cancer.
  • the invention provides of a group of genes useful in diagnosing lung diseases, wherein the expression of the group of genes is lower in individuals exposed to air pollutants with cancer as compared to individuals exposed to the same air pollutant who do not have cancer, the group comprising probes that hybridize at least 5, preferably at least about 5-10, still more preferably at least about 10-20, still more preferably at least about 20-30, still more preferably at least about 30-40, still more preferably at least about 40-50, still more preferably at least about 50-60, still more preferably at least about 60-70, still more preferably about 72 genes consisting of transcripts (transcripts are identified using their Genbank ID or Unigene ID numbers and the corresponding gene names appear in Table 1): NM — 003335; NM — 001319; NM — 021145.1; NM — 001003698///NM — 001003699///; NM — 002955; NM — 002853.1; NM —
  • the invention provides of a group of genes useful in diagnosing lung diseases wherein the expression of the group of genes is lower in individuals exposed to air pollutants with cancer as compared to individuals exposed to the same air pollutant who do not have cancer, the group comprising probes that hybridize at least 5, preferably at least about 5-10, still more preferably at least about 10-20, still more preferably at least about 20-30, still more preferably at least about 3040, still more preferably at least about 40-50, still more preferably at least about 50-60, still more preferably about 63 genes consisting of transcripts (transcripts are identified using their GenBank ID or Unigene ID numbers and the corresponding gene names appear in Table 2): NM — 030757.1; R83000; AK021571.1; NM — 17932.1; U85430.1; A1683552; BC002642.1; AW024467; NM — 030972.1; BC021135.1; AL161952.1; AK026565.1; AK023783.1; BF2188
  • the invention provides of a group of genes useful in diagnosing lung diseases wherein the expression of the group of genes is lower in individuals exposed to air pollutants with cancer as compared to individuals exposed to the same air pollutant who do not have cancer, the group comprising probes that hybridize at least 5, preferably at least about 5-10, still more preferably at least about 10-20, still more preferably at least about 20-25, still more preferably about 25 genes consisting of transcripts (transcripts are identified using their GenBank ID or Unigene ID numbers and the corresponding gene names appear in Table 3): BF218804; AK022494.1; AA114843; BE467941; NM — 003541.1; R83000; AL161952.1; AK023843.1; AK021571.1; AK023783.1; AU147182; AL080112.1; AW971983; AI683552; NM — 024006.1; AK026565.1; NM — 014182.1; NM — 021800.1
  • the invention provides of a group of genes useful in diagnosing lung diseases wherein the expression of the group of genes is higher in individuals exposed to air pollutants with cancer as compared to individuals exposed to the same air pollutant who do not have cancer, the group comprising probes that hybridize at least to 5, preferably at least about 5-10, still more preferably at least about 10-20, still more preferably at least about 20-25, still more preferably about 25 genes consisting of transcripts (transcripts are identified using their GenBank ID or Unigene ID numbers and the corresponding gene names appear in Table 1): NM — 000918; NM — 006430.1; NM — 001416.1; NM — 004090; NM — 006406.1; NM — 003001.2; NM — 006545.1; NM — 002437.1; NM — 006286; NM — 001123//NM — 006721; NM — 024824; NM — 004935.1;
  • the invention provides of a group of genes useful in diagnosing lung diseases wherein the expression of the group of genes is higher in individuals exposed to air pollutants with cancer as compared to individuals exposed to the same air pollutant who do not have cancer, the group comprising probes that hybridize at least to 5, preferably at least about 5-10, still more preferably at least about 10-20, still more preferably at least about 20-23, still more preferably about 23 genes consisting of transcripts (transcripts are identified using their Genbank ID or Unigene ID numbers and the corresponding gene names appear in Table 2): NM — 014182.1; NM — 001281.1; NM — 024006.1; AF135421.1; L76200.1; NM — 000346.1; BC008710.1; BC000423.2; BC008710.1; NM — 007062; BC075839.1///BC073760.1; BC072436.1///BC004560.2; BC001016.2; BC005023.1; BC000360.2; BC007
  • the invention provides of a group of genes useful in diagnosing lung diseases wherein the expression of the group of genes is higher in individuals exposed to air pollutants with cancer as compared to individuals exposed to the same air pollutant who do not have cancer, the group comprising probes that hybridize at least to 5, preferably at least about 5-10, still more preferably at least about 10-20, still more preferably at least about 20-25, still more preferably about 25 genes consisting of transcripts (transcripts are identified using their GenBank ID or Unigene ID numbers and the corresponding gene names appear in Table 3): NM — 007062.1; NM — 001281.1; BC000120.1; NM — 014255.1; BC002642.1; NM — 000346.1; NM — 006545.1; BG034328; NM — 021822.1; NM — 021069.1; NM — 019067.1; NM — 017925.1; NM — 017932.1; NM — 030757.1
  • the invention provides a method of diagnosing lung disease comprising the steps of measuring the expression profile of a gene group in an individual suspected of being affected or being at high risk of a lung disease (i.e. test individual), and comparing the expression profile (i.e. control profile) to an expression profile of an individual without the lung disease who has also been exposed to similar air pollutant than the test individual (i.e.
  • Groups of about 36 genes as shown in table 4, about 50 genes as shown in table 3, about 84 genes as shown in table 2 and about 96 genes as shown in table 1 are preferred.
  • the different gene groups can also be combined, so that the test individual can be screened for all, three, two, or just one group as shown in tables 1-4.
  • the expression profile of a test individual exposed to cigarette smoke is compared to the expression profile of the 50 genes shown in table 3, using the Affymetrix Inc. probe set on a gene chip as shown in table 3, the expression profile that is similar to the one shown in FIG. 10 for the individuals with cancer, is indicative that the test individual has cancer.
  • the expression profile is more like the expression profile of the individuals who do not have cancer in FIG. 10 , the test individual likely is not affected with lung cancer.
  • the group of 50 genes was identified using the GenePattern server from the Broad Institute, which includes the Weighted Voting algorithm. The default settings, i.e., the signal to noise ratio and no gene filtering, were used. GenePattern is available through the World Wide Wed at location broad.mit.edu/cancer/software/genepattern. This program allows analysis of data in groups rather than as individual genes. Thus, in one preferred embodiment, the expression of substantially all 50 genes of Table 3, are analyzed together.
  • the expression pattern of all the genes in the Table 3 is analyzed.
  • 1, 2, 3, 4, 5, 6, 7, 8, 9, 10-15, 15-20, 20-30, or more of the individual predictor genes identified using the t-test analysis are analyzed. Any combination of, for example, 5-10 or more of the group predictor genes and 5-10, or more of the individual genes can also be used.
  • expression profile refers to the amount of the gene product of each of the analyzed individual genes in the sample.
  • the “expression profile” is like a signature expression map, like the one shown for each individual in FIG. 10 , on the Y-axis.
  • lung disease refers to disorders including, but not limited to, asthma, chronic bronchitis, emphysema, bronchietasis, primary pulmonary hypertension and acute respiratory distress syndrome.
  • the methods described herein may also be used to diagnose or treat lung disorders that involve the immune system including, hypersensitivity pneumonitis, eosinophilic pneumonias, and persistent fungal infections, pulmonary fibrosis, systemic sclerosis, idiopathic pulmonary hemosiderosis, pulmonary alveolar proteinosis, cancers of the lung such as adenocarcinoma, squamous cell carcinoma, small cell and large cell carcinomas, and benign neoplasm of the lung including bronchial adenomas and hamartomas.
  • the lung disease is lung cancer.
  • air pollutants refers to any air impurities or environmental airway stress inducing agents, such as cigarette smoke, cigar smoke, smog, asbestos, and other air pollutants that have suspected or proven association to lung diseases.
  • laboratory test animals preferably animals that have lungs, such as non-human primates, murine species, including, but not limited to rats and mice, dogs, sheep, pig, guinea pigs, and other model animals.
  • laboratory tests can be used, for example in pre-clinical animal testing of drugs intended to be used to treat or prevent lung diseases.
  • altered expression refers to either increased or decreased expression in an individual exposed to air pollutant, such as a smoker, with cancer when compared to an expression pattern of the lung cells from an individual exposed to similar air pollutant, such as smoker, who does not have cancer.
  • Tables 1 and 2 show the preferred expression pattern changes of the invention.
  • the terms “up” and “down” in the tables refer to the amount of expression in a smoker with cancer to the amount of expression in a smoker without cancer. Similar expression pattern changes are likely associated with development of cancer in individuals who have been exposed to other airway pollutants.
  • the group of genes the expression of which is analyzed in diagnosis and/or prognosis of lung cancer are selected from the group of 80 genes as shown in Table 5. Any combination of genes can be selected from the 80 genes. In one embodiment, the combination of 20 genes shown in Table 7 is selected. In one embodiment, a combination of genes from Table 6 is selected.
  • Affymetrix Gene symbol Number of Signal to noise in a ID runs* cancer sample** 200729_s_at ACTR2 736 ⁇ 0.22284 200760_s_at ARL6IP5 483 ⁇ 0.21221 201399_s_at TRAM1 611 ⁇ 0.21328 201444_s_at ATP6AP2 527 ⁇ 0.21487 201635_s_at FXR1 458 ⁇ 0.2162 201689_s_at TPD52 565 ⁇ 0.22292 201925_s_at DAF 717 ⁇ 0.25875 201926_s_at DAF 591 ⁇ 0.23228 201946_s_at CCT2 954 ⁇ 0.24592 202118_s_at CPNE3 334 ⁇ 0.21273 202704_at TOB1 943 ⁇ 0.25724 202833_s_at SERPINA1 576 ⁇ 0.20583 202935_s_at SOX9 750
  • one uses at least one, preferably at least 2, 3, 4, 5, 6, 7, 8, 9, 10 or more, of the genes as listed in Tables 8, 9 and/or 10. In one embodiment, one uses maximum of 500, 400, 300, 200, 100, or 50 of the gene that include at least 5, 6, 7, 8, 9, 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 1-70, of the genes listed in Tables 8-10.
  • the analysis of the gene expression of one or more genes and/or transcripts of the groups or their subgroups of the present invention can be performed using any gene expression method known to one skilled in the art. Such methods include, but are not limited to expression analysis using nucleic acid chips (e.g. Affymetrix chips) and quantitative RT-PCR based methods using, for example real-time detection of the transcripts. Analysis of transcript levels according to the present invention can be made using total or messenger RNA or proteins encoded by the genes identified in the diagnostic gene groups of the present invention as a starting material.
  • nucleic acid chips e.g. Affymetrix chips
  • quantitative RT-PCR based methods using, for example real-time detection of the transcripts.
  • Analysis of transcript levels according to the present invention can be made using total or messenger RNA or proteins encoded by the genes identified in the diagnostic gene groups of the present invention as a starting material.
  • the analysis is an immunohistochemical analysis with an antibody directed against proteins comprising at least about 10-20, 20-30, preferably at least 36, at least 36-50, 50, about 50-60, 60-70, 70-80, 80-90, 96,100-180, 180-200, 200-250, 250-300, 300-350,350-400, 400-450, 450-500, 500-535 proteins encoded by the genes and/or transcripts as shown in Tables 1-7.
  • the methods of analyzing transcript levels of the gene groups in an individual include Northern-blot hybridization, ribonuclease protection assay, and reverse transcriptase polymerase chain reaction (RT-PCR) based methods.
  • RT-PCR reverse transcriptase polymerase chain reaction
  • the different RT-PCR based techniques are the most suitable quantification method for diagnostic purposes of the present invention, because they are very sensitive and thus require only a small sample size which is desirable for a diagnostic test.
  • a number of quantitative RT-PCR based methods have been described and are useful in measuring the amount of transcripts according to the present invention.
  • RNA quantification using PCR and complementary DNA (cDNA) arrays (Shalon et al., Genome Research 6(7):63945, 1996; Bernard et al., Nucleic Acids Research 24(8): 143542, 1996), real competitive PCR using a MALDI-TOF Mass spectrometry based approach (Ding et al, PNAS, 100: 3059-64, 2003), solid-phase mini-sequencing technique, which is based upon a primer extension reaction (U.S. Pat. No. 6,013,431, Suomalainen et al. Mol. Biotechnol. June; 15(2): 123-31, 2000), ion-pair high-performance liquid chromatography (Doris et al.
  • the samples are preferably obtained from bronchial airways using, for example, endoscopic cytobrush in connection with a fiber optic bronchoscopy.
  • the cells are obtained from the individual's mouth buccal cells, using, for example, a scraping of the buccal mucosa.
  • the invention provides a prognostic and/or diagnostic immunohistochemical approach, such as a dip-stick analysis, to determine risk of developing lung disease.
  • Antibodies against proteins, or antigenic epitopes thereof, that are encoded by the group of genes of the present invention, are either commercially available or can be produced using methods well know to one skilled in the art.
  • the invention contemplates either one dipstick capable of detecting all the diagnostically important gene products or alternatively, a series of dipsticks capable of detecting the amount proteins of a smaller sub-group of diagnostic proteins of the present invention.
  • Antibodies can be prepared by means well known in the art.
  • the term “antibodies” is meant to include monoclonal antibodies, polyclonal antibodies and antibodies prepared by recombinant nucleic acid techniques that are selectively reactive with a desired antigen.
  • Antibodies against the proteins encoded by any of the genes in the diagnostic gene groups of the present invention are either known or can be easily produced using the methods well known in the art. Internet sites such as Biocompare through the World Wide Web at biocompare.com at abmatrix to provide a useful tool to anyone skilled in the art to locate existing antibodies against any of the proteins provided according to the present invention.
  • Antibodies against the diagnostic proteins according to the present invention can be used in standard techniques such as Western blotting or immunohistochemistry to quantify the level of expression of the proteins of the diagnostic airway proteome. This is quantified according to the expression of the gene transcript, i.e. the increased expression of transcript corresponds to increased expression of the gene product, i.e. protein. Similarly decreased expression of the transcript corresponds to decreased expression of the gene product or protein.
  • Tables 5 and 6 describe a group of genes the expression of which is altered in lung cancer.
  • Immunohistochemical applications include assays, wherein increased presence of the protein can be assessed, for example, from a saliva or sputum sample.
  • the immunohistochemical assays according to the present invention can be performed using methods utilizing solid supports.
  • the solid support can be a any phase used in performing immunoassays, including dipsticks, membranes, absorptive pads, beads, microtiter wells, test tubes, and the like.
  • test devices which may be conveniently used by the testing personnel or the patient for self-testing, having minimal or no previous training.
  • Such preferred test devices include dipsticks, membrane assay systems as described in U.S. Pat. No. 4,632,901. The preparation and use of such conventional test systems is well described in the patent, medical, and scientific literature.
  • the anti-protein antibody is bound to one end of the stick such that the end with the antibody can be dipped into the solutions as described below for the detection of the protein.
  • the samples can be applied onto the antibody-coated dipstick or membrane by pipette or dropper or the like.
  • the antibody against proteins encoded by the diagnostic airway transcriptome can be of any isotype, such as IgA, IgG or IgM, Fab fragments, or the like.
  • the antibody may be a monoclonal or polyclonal and produced by methods as generally described, for example, in Harlow and Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, 1988, incorporated herein by reference.
  • the antibody can be applied to the solid support by direct or indirect means. Indirect bonding allows maximum exposure of the protein binding sites to the assay solutions since the sites are not themselves used for binding to the support.
  • polyclonal antibodies are used since polyclonal antibodies can recognize different epitopes of the protein thereby enhancing the sensitivity of the assay.
  • the solid support is preferably non-specifically blocked after binding the protein antibodies to the solid support.
  • Non-specific blocking of surrounding areas can be with whole or derivatized bovine serum albumin, or albumin from other animals, whole animal serum, casein, non-fat milk, and the like.
  • the sample is applied onto the solid support with bound protein-specific antibody such that the protein will be bound to the solid support through said antibodies. Excess and unbound components of the sample are removed and the solid support is preferably washed so the antibody-antigen complexes are retained on the solid support.
  • the solid support may be washed with a washing solution which may contain a detergent such as Tween-20, Tween-80 or sodium dodecyl sulfate.
  • the second antibody which reacts with protein is applied.
  • the second antibody may be labeled, preferably with a visible label.
  • the labels may be soluble or particulate and may include dyed immunoglobulin binding substances, simple dyes or dye polymers, dyed latex beads, dye-containing liposomes, dyed cells or organisms, or metallic, organic, inorganic, or dye solids.
  • the labels may be bound to the protein antibodies by a variety of means that are well known in the art.
  • the labels may be enzymes that can be coupled to a signal producing system.
  • visible labels examples include alkaline phosphatase, beta-galactosidase, horseradish peroxidase, and biotin. Many enzyme-chromogen or enzyme-substrate-chromogen combinations are known and used for enzyme-linked assays. Dye labels also encompass radioactive labels and fluorescent dyes.
  • corresponding steps may be carried out with a known amount or amounts of the protein and such a step can be the standard for the assay.
  • a sample from a healthy individual exposed to a similar air pollutant such as cigarette smoke, can be used to create a standard for any and all of the diagnostic gene group encoded proteins.
  • the solid support is washed again to remove unbound labeled antibody and the labeled antibody is visualized and quantified.
  • the accumulation of label will generally be assessed visually. This visual detection may allow for detection of different colors, for example, red color, yellow color, brown color, or green color, depending on label used. Accumulated label may also be detected by optical detection devices such as reflectance analyzers, video image analyzers and the like.
  • the visible intensity of accumulated label could correlate with the concentration of protein in the sample.
  • the correlation between the visible intensity of accumulated label and the amount of the protein may be made by comparison of the visible intensity to a set of reference standards.
  • the standards have been assayed in the same way as the unknown sample, and more preferably alongside the sample, either on the same or on a different solid support.
  • the concentration of standards to be used can range from about 1 mg of protein per liter of solution, up to about 50 mg of protein per liter of solution.
  • concentrations of an airway gene group encoded proteins are used so that quantification of the unknown by comparison of intensity of color is more accurate.
  • the present invention provides a method for detecting risk of developing lung cancer in a subject exposed to cigarette smoke comprising measuring the transcription profile in a nasal epithelial cell sample of the proteins encoded by one or more groups of genes of the invention in a biological sample of the subject.
  • a biological sample of the subject Preferably at least about 30, still more preferably at least about 36, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, or about 180 of the proteins encoded by the airway transcriptome in a biological sample of the subject are analyzed.
  • the method comprises binding an antibody against each protein encoded by the gene in the gene group (the “protein”) to a solid support chosen from the group consisting of dip-stick and membrane; incubating the solid support in the presence of the sample to be analyzed under conditions where antibody-antigen complexes form; incubating the support with an anti-protein antibody conjugated to a detectable moiety which produces a signal; visually detecting said signal, wherein said signal is proportional to the amount of protein in said sample; and comparing the signal in said sample to a standard, wherein a difference in the amount of the protein in the sample compared to said standard of the same group of proteins, is indicative of diagnosis of or an increased risk of developing lung cancer.
  • the standard levels are measured to indicate expression levels in an airway exposed to cigarette smoke where no cancer has been detected.
  • the assay reagents, pipettes/dropper, and test tubes may be provided in the form of a kit. Accordingly, the invention further provides a test kit for visual detection of the proteins encoded by the airway gene groups, wherein detection of a level that differs from a pattern in a control individual is considered indicative of an increased risk of developing lung disease in the subject.
  • the test kit comprises one or more solutions containing a known concentration of one or more proteins encoded by the airway transcriptome (the “protein”) to serve as a standard; a solution of a anti-protein antibody bound to an enzyme; a chromogen which changes color or shade by the action of the enzyme; a solid support chosen from the group consisting of dip-stick and membrane carrying on the surface thereof an antibody to the protein. Instructions including the up or down regulation of the each of the genes in the groups as provided by the Tables 1 and 2 are included with the kit.
  • the practice of the present invention may employ, unless otherwise indicated, conventional techniques and descriptions of organic chemistry, polymer technology, molecular biology (including recombinant techniques), cell biology, biochemistry, and immunology, which are within the skill of the art.
  • Such conventional techniques include polymer array synthesis, hybridization, ligation, and detection of hybridization using a label. Specific illustrations of suitable techniques can be had by reference to the example herein below. However, other equivalent conventional procedures can, of course, also be used.
  • Such conventional techniques and descriptions can be found in standard laboratory manuals such as Genome Analysis: A Laboratory Manual Series (Vols.
  • the methods of the present invention can employ solid substrates, including arrays in some preferred embodiments.
  • Methods and techniques applicable to polymer (including protein) array synthesis have been described in U.S. Ser. No. 09/536,841, WO 00/58516, U.S. Pat. Nos.
  • Patents that describe synthesis techniques in specific embodiments include U.S. Pat. Nos. 5,412,087, 6,147,205, 6,262,216, 6,310,189, 5,889,165, and 5,959,098. Nucleic acid arrays are described in many of the above patents, but the same techniques are applied to polypeptide and protein arrays.
  • Nucleic acid arrays that are useful in the present invention include, but are not limited to those that are commercially available from Affymetrix (Santa Clara, Calif.) under the brand name GeneChip7. Example arrays are shown on the website at affymetrix.com.
  • the present invention also contemplates sample preparation methods in certain preferred embodiments.
  • the nucleic acid sample may be amplified by a variety of mechanisms, some of which may employ PCR. See, e.g., PCR Technology: Principles and Applications for DNA Amplification (Ed. H. A. Erlich, Freeman Press, NY, N.Y., 1992); PCR Protocols: A Guide to Methods and Applications (Eds. Innis, et al., Academic Press, San Diego, Calif., 1990); Mattila et al., Nucleic Acids Res. 19, 4967 (1991); Eckert et al., PCR Methods and Applications 1, 17 (1991); PCR (Eds.
  • LCR ligase chain reaction
  • LCR ligase chain reaction
  • Landegren et al. Science 241, 1077 (1988) and Barringer et al. Gene 89:117 (1990)
  • transcription amplification Kwoh et al., Proc. Natl. Acad. Sci. USA 86, 1173 (1989) and WO88/10315
  • self-sustained sequence replication Guatelli et al., Proc. Nat. Acad. Sci. USA, 87, 1874 (1990) and WO90/06995
  • selective amplification of target polynucleotide sequences U.S. Pat. No.
  • the present invention also contemplates signal detection of hybridization between the sample and the probe in certain embodiments. See, for example, U.S. Pat. Nos. 5,143,854, 5,578,832; 5,631,734; 5,834,758; 5,936,324; 5,981,956; 6,025,601; 6,141,096; 6,185,030; 6,201,639; 6,218,803; and 6,225,625, in provisional U.S. Patent application 60/364,731 and in PCT Application PCT/US99/06097 (published as WO99/47964).
  • Computer software products of the invention typically include computer readable medium having computer-executable instructions for performing the logic steps of the method of the invention.
  • Suitable computer readable medium include floppy disk, CD-ROM/DVD/DVD-ROM, hard-disk drive, flash memory, ROM/RAM, magnetic tapes and etc.
  • the computer executable instructions may be written in a suitable computer language or combination of several languages. Basic computational biology methods are described in, e.g.
  • the present invention also makes use of various computer program products and software for a variety of purposes, such as, probe design, management of data, analysis, and instrument operation. See, for example, U.S. Pat. Nos. 5,593,839, 5,795,716, 5,733,729, 5,974,164, 6,066,454, 6,090,555, 6,185,561, 6,188,783, 6,223,127, 6,229,911 and 6,308,170.
  • the present invention may have embodiments that include methods for providing gene expression profile information over networks such as the Internet as shown in, for example, U.S. patent application Ser. Nos. 10/063,559, 60/349,546, 60/376,003, 60/394,574, 60/403,381.
  • fractional ranges are also included in the exemplified amounts that are described. Therefore, for example, a range of 1-3 includes fractions such as 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, etc. This applies particularly to the amount of increase or decrease of expression of any particular gene or transcript.
  • RNA/DNA nucleic acid samples from nose epithelial cells.
  • nucleic acids from blood to provide one control.
  • PCT/US2006/014132 we used our findings in the PCT/US2006/014132 to compare the gene expression profile in the bronchial epithelial cells as disclosed in the PCT/US2006/014132 to the gene expression pattern discovered in this example from the nasal epithelial cells.
  • allelic loss occurs throughout the intra-pulmonary airways in smokers with lung cancer, on the side of the cancer as well as the opposite side from the cancer. Allelic loss also occurs, but to a lesser extent, in airway epithelial cells of smokers without cancer (Clinical Cancer Research 5:2025, 1999).
  • epithelial cells obtained by brushing the nasal mucosa could be used as a diagnostic and prognostic tool for lung disorders.
  • Preliminary results show that we can obtain abundant amounts of high quality RNA and DNA from the nose with ease (see protocol below), that we can measure gene expression using this RNA and high density microarrays and that many of the genes that change with smoking in the bronchial epithelium also change in the nose (see FIG. 1 ).
  • gene expression in nasal epithelium can be used to define a potentially diagnostic and clinical stage-specific pattern of gene expression in subjects with sarcoidosis, even when the sarcoidosis does not clinically involve the lung (see FIG. 2 ).
  • We can also obtain DNA from these same specimens allowing us to assess gene methylation patterns and genetic polymorphisms that explain changes in gene expression.
  • a Cytosoft brush is inserted into the right nare and under the inferior turbinate using a nasal speculum for visualization.
  • the brush is turned 3 times to collect epithelial cells and immediately placed into RNA Later. Repeat brushing is performed and the 2nd brush is placed in PBS for DNA isolation.
  • buccal mucosa epithelial samples from 10 subjects (5 never smokers, 5 current smokers) using a scraping device that we have described previously [38] (see Appendix). All samples were run on Affymetrix HG-U133A arrays. Due to the small amounts (1-2 ug) of partially degraded RNA obtained from the mouth, samples were collected serially on each subject monthly and pooled to yield sufficient RNA (6-8 ug), Low transcript detection rates were observed for mouth samples, likely as a result of lower levels of intact full-length mRNA in the mouth samples
  • GSEA Gene Set Enrichment Analysis
  • Cigarette smoking has been found to induce a number of changes in both the upper and lower respiratory tract epithelia including cellular atypia (3, 4), aberrant gene expression, loss of heterozygosity (3, 5) and promoter hypermethylation.
  • cellular atypia 3, 4
  • aberrant gene expression 3, 5
  • promoter hypermethylation 3, 5
  • molecular and genetic changes such as LOH or microsatellite alterations dispersed throughout the airway epithelium of smokers including areas that are histologically normal (4, 6).
  • Oral and nasal mucosa are attractive candidates for a biomarkers since they are exposed to high concentrations of inhaled carcinogens and are definitively linked to smoking-related diseases (8).
  • RNA for cDNA microarrays found approximately 100 genes that could distinguish the two groups in training and test sets. While the study provided encouraging evidence that buccal gene expression changes with smoking, many of these genes were undefined ESTs, and the study did not address any potential relationship between genetic responses in the upper and lower airways.
  • Spivak et. al. found a qualitative relationship via PCR (i.e. detected or not detected) between patient matched buccal mucosa and laser-dissected lung epithelial cells across nine carcinogen or oxidant-metabolizing genes (13) in 11 subjects being evaluated for lung cancer.
  • Microarrays were performed on total of 25 subjects and mass spectrometry validation on 14 additional subjects. Demographic data for the microarray and mass spectrometry validation groups are presented in Table 11.
  • Microarray analysis of normal tissue samples was performed on previously published datasets collected from the Gene Expression Omnibus (GEO). Ninety two samples spanning 10 different tissues types were analyzed altogether, including 12 nasal and buccal epithelial samples of non-smokers collected for this study. Additional microarray data from normal nasal epithelial samples were also collected to determine the reproducibility of gene expression patterns in nasal tissue collected from a different study. A detailed breakdown of the different tissues analyzed and number of samples within each tissue type are shown in Table 12.
  • GEO Gene Expression Omnibus
  • PCA Principal component analysis
  • genes from functional groups commonly expressed in airway epithelium were selected from among the normal airway transcriptome.
  • Genes from the mucin, dynein, microtubule, keratin, glutathione, cytochrome P450, and aldehyde dehydrogenase functional groups were selected from among the 2382 genes in the normal airway transcriptome, based on their gene annotations. Fifty-nine genes from these functional groups were present among the normal airway transcriptome and analyzed using supervised hierarchical clustering, as shown in FIG. 8 .
  • keratins were expressed specifically in skin and esophageal epithelium
  • other keratins such as KRT7, KRT8, KRT18, and KRT19 were expressed primarily in bronchial and nasal epithelium.
  • mucin genes with MUC4, MUC5AC, and MUC16 being expressed primarily in bronchial and nasal epithelium
  • MUC1 was expressed in other epithelial tissues.
  • Glutathione genes were expressed highly in bronchial and nasal epithelium as well as other tissues. Microtubule expression was fairly even across all tissues.
  • a metagene was created by selected a subset of the 59 functionally relevant normal transcriptome genes with highly correlated expression in between bronchial and nasal samples All genes which were highly correlated to the metagene (R>0.6, p ⁇ 0.001) were selected and analyzed using EASE to determine sets functionally overrepresented categories. The microtubule and cytoskeletal complex functional set was significantly enriched among the genes most highly correlated with the expression pattern of the metagene.
  • This separate nasal epithelial dataset consisted of 11 normal epithelial samples run on Affymetrix HG133A microarrays. These samples were first examined with the 92 normal tissue samples from previous analysis. A correlation matrix was created to determine the average pearson correlation of each set of samples within a tissue type with samples from other tissue types. The two nasal epithelial datasets had the highest correlation with each other, with the next highest correlation being between nasal and bronchial epithelial samples.
  • These 11 nasal epithelial samples also clustered together with bronchial epithelial samples across the entire normal transcriptome and the subset of 59 functionally relevant genes from the transcriptome when used in place of our original 8 nasal epithelial samples.
  • the 361 genes as shown in Table 8 most differently expressed in the airway epithelial cells of current and never smokers were generally able to distinguish bronchial, nasal, and buccal epithelial samples based on smoking status using principal component analysis, with few exceptions among buccal mucosa samples ( FIG. 3 ). This finding suggests a relationship between gene expression profiles in epithelial cells in the bronchus and upper airway epithelium in response to cigarette smoke. To further establish this connection across airway epithelial cells, gene set enrichment analysis (GSEA) was performed to determine if genes most differentially expressed in bronchial epithelium based on smoking status were overrepresented among the genes that change with smoking in both nasal and buccal epithelium.
  • GSEA gene set enrichment analysis
  • the leading edge subset consists of the genes that contribute most to the enrichment of airway genes in buccal mucosa samples.
  • FIG. 6 similarly shows that the genes differing most across the bronchial epithelium of smokers were also significantly enriched among the genes most affected by smoking in nasal epithelial cell samples, with 107 genes comprising the leading edge subset (p ⁇ 0.001).
  • PCA of the leading edge genes show that they are able to separate buccal mucosa samples and nasal epithelial samples ( FIG.
  • Buccal epithelial cells were collected on 25 subjects (11 for the buccal microarray study, 14 for the mass spectrometry validation) as previously reported (Spira et. al. 2004, Biotechniques). Briefly, we developed a non-invasive method for obtaining small amounts of RNA from the mouth using a concave plastic tool with serrated edges. Using gentle pressure, the serrated edge was scraped 5 times against the buccal mucosa on the inside left cheek and placed immediately into 1 mL of RNALATER (Qiagen, Valencia, Calif.). The procedure was repeated for the inside right cheek and the cellular material was combined into one tube.
  • RNALATER Qiagen, Valencia, Calif.
  • RNA was isolated from the cell pellet using TRIZOL® reagent (Invitrogen, Carlsbad, Calif.) according to the manufacturer's protocol. The integrity of the RNA was confirmed on an RNA denaturing gel. Epithelial cell content was quantified by cytocentrifugation at 700 ⁇ g (Cytospin, ThermoShandon, Pittsburgh, Pa.) of the cell pellet and staining with a cytokeratin antibody (Signet, Dedham, Mass.). Using this protocol, we were able to obtain an average of 1823 ng+/ ⁇ 1243 ng of total RNA per collection. Buccal epithelial cells were collected serially over 6 weeks in order to obtain a minimum of 8 ug of RNA per subject. For the 14 subjects included in the mass spectrometry validation, a single collection was sufficient.
  • Nasal epithelial cells were collected by first anesthesizing the right nare with Icc of 1% lidocaine. A nasal speculum (Bionix, Toledo Ohio) was use to spread the nare while a standard cytology brush (Cytosoft Brush, Medical Packaging Corporation, Camarillo Calif.) was inserted underneath the inferior nasal turbinate. The brush was rotated in place once, removed, and immediately placed in 1 mL RNA Later (Qiagen, Valencia, Calif.). After storage at 4 degrees overnight, RNA was isolated via Qiagen RNEASY® Mini Kits per manufacturer's protocol. As above, the integrity of RNA was confirmed with an RNA denaturing gel and epithelial cell content was quantified by cytocentrifugation.
  • Affymetrix HG-U133A GeneChips containing 22,215 probe sets as previously described (Spira et. al, 2004, PNAS).
  • a single weighted mean expression level for each gene was derived using MICROARRAY SUITE 5.0 (MAS 5.0) software (Affymetrix, Santa Clara, Calif.).
  • the MAS 5.0 software also generated a detection P value [P(detection)] using a one-sided Wilcoxon sign-ranked test, which indicated whether the transcript was reliably detected.
  • One buccal mucosa microarray sample was excluded from further analysis based on the percentage of genes detected being lower than two standard deviations from the median percentage detected across all buccal mucosa microarray samples, leaving 10 samples for further analysis. All 15 nasal epithelial cell microarray samples contained sufficiently high percentages of genes detected based on the same criteria, and were all included for further analysis. Microarray data from 57 bronchial epithelial cell samples was obtained from previously published data (Spira et. al, 2004, PNAS).
  • Microarray data from 7 additional normal human tissues was obtained from datasets in the Gene Expression Omnibus (GEO). The samples were selected from normal, non-diseased tissue, where there were at least 5 samples per tissue type. All samples were run on either Affymetrix HGU133A or HGU133 Plus 2.0 microarrays. Array data from normal tissue samples from the following 7 tissues were used (GEO accession number included): lung (GSE1650), skin (GSE5667), esophagus (GSE1420), kidney (GSE3526), bone marrow (GSE3526), heart (GSE2240), and brain (GSE5389). A detailed breakdown of the array data obtained for these tissues can be seen in Table 12.
  • Microarray data from buccal mucosa, nasal epithelium, and bronchial epithelial cell samples, as well at normal tissue samples from the 8 datasets listed above were each normalized using MAS 5.0, where the mean intensity for each array (excluding the top and bottom 2% of genes) was corrected using a scaling factor to set the average target intensity of all probes on the chip to 100.
  • tissue samples run on the HGU133 Plus 2.0 arrays only those probe sets in common with the HGU133A array were selected and normalized using MATLAB Student Version 7.1 (The Mathworks, Inc.), where the mean intensity of the selected probes (excluding the top and bottom 2% of genes) was corrected using a scaling factor to set the average target intensity of the remaining probes to 100.
  • Clinical information, array data, and gene annotations are stored in an interactive MYSQL database coded in PERL (37). All statistical analyses described below and within the database were performed using the R v. 2.2.0 software (38). The gene annotations used for each probe set were from the December 2004 NetAffx HG-U133A annotation files.
  • PCA Principal component analysis
  • Functional annotation clustering was performed using the EASE software package (40) to determine overrepresented sets of functional groups (“functional sets”) among the normal airway transcriptome. Each functional group within a cluster was given a p-value, determined by a Fisher-Exact test. The significance of the functional cluster was then determined by taking the geometric mean of the p-values of each functional group in the cluster. To limit the number of functional sets returned by EASE, only functional groups from the Gene Ontology (GO) database below the 5th hierarchical node were used.
  • GO Gene Ontology
  • V X ⁇ (1 . . . i )[ COV ( X ⁇ G 1 . . . X ⁇ Gk ))]
  • Gk is the expression of gene G across all the samples in tissue type k
  • i is the total number of genes in a functional cluster
  • COV is the coefficient of variation (standard deviation divided by mean) of the average expression of gene G across all tissue types. This produced one variability metric (V) for each functional cluster. All the genes in each functional cluster were then analyzed using 2D hierarchical clustering performed by using log-transformed z-score normalized data with a Pearson correlation (uncentered) similarity metric and average linkage clustering with CLUSTER and TREEVIEW software (41).
  • genes from the normal airway transcriptome included in functional categories commonly expressed in airway epithelial cells were examined.
  • the functional categories explored were mucin, dynein, microtubule, cytochrome p450, glutathione, aldehyde dehydrogenase, and keratin. Genes from these categories were determined by selecting all those genes from the normal airway transcriptome that were also included in any of these functional groups based on their gene annotation. Fifty-nine genes from the normal airway transcriptome which also spanned the functional categories of interest were further analyzed across the 10 tissues types using supervised hierarchical clustering.
  • a second nasal epithelial dataset (Wright et. al, 2006, Am J Respir Cell Mol Biol.) was included for further analysis to determine the reproducibility of the expression patterns observed in nasal epithelium compared to other tissues.
  • 11 nasal epithelial samples from this second dataset (GSE2395) which were used in place of our original 8 nasal samples to determine the reproducibility of gene expression patterns and relationships between nasal epithelium and other tissues.
  • PCA was performed across 82 smoker and non-smoker samples (57 bronchial, 10 buccal, 15 nasal) using 361 genes differentially expressed between smokers and non-smokers in bronchial epithelial cells (p ⁇ 0.001), as determined from a prior study (Spira et. al, 2004, PNAS).
  • GSEA Gene set enrichment analysis
  • Table 12 shows breakdown of all microarry datasets analyzed in this study.
  • Table 13 below shows Significantly overrepresented “functional sets” among the normal airway transcriptome. Sixteen functional sets significantly overrepresented among the normal airway transcriptome, ranked by the variability of each cluster across 10 issue types.
  • Table 14 shows Common overrepresented functional categories among “leading edge subsets” from GSEA analysis. Common EASE molecular functions of leading edge genes from GSEA analysis. P-values were calculated using EASE software.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
US12/282,320 2006-03-09 2007-03-08 Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells Abandoned US20090061454A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/282,320 US20090061454A1 (en) 2006-03-09 2007-03-08 Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78055206P 2006-03-09 2006-03-09
US12/282,320 US20090061454A1 (en) 2006-03-09 2007-03-08 Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
PCT/US2007/006006 WO2007103541A2 (fr) 2006-03-09 2007-03-08 Méthodes de diagnostic et de pronostic pour troubles des poumons utilisant des profils d'expression de gènes de cellules épithéliales nasales

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/006006 A-371-Of-International WO2007103541A2 (fr) 2006-03-09 2007-03-08 Méthodes de diagnostic et de pronostic pour troubles des poumons utilisant des profils d'expression de gènes de cellules épithéliales nasales

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/940,840 Continuation US20110217717A1 (en) 2006-03-09 2010-11-05 Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells

Publications (1)

Publication Number Publication Date
US20090061454A1 true US20090061454A1 (en) 2009-03-05

Family

ID=38328561

Family Applications (5)

Application Number Title Priority Date Filing Date
US12/282,320 Abandoned US20090061454A1 (en) 2006-03-09 2007-03-08 Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
US12/940,840 Abandoned US20110217717A1 (en) 2006-03-09 2010-11-05 Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
US13/323,655 Abandoned US20120190567A1 (en) 2006-03-09 2011-12-12 Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
US14/690,182 Abandoned US20170328908A1 (en) 2006-03-09 2015-04-17 Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
US16/579,798 Active US11977076B2 (en) 2006-03-09 2019-09-23 Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells

Family Applications After (4)

Application Number Title Priority Date Filing Date
US12/940,840 Abandoned US20110217717A1 (en) 2006-03-09 2010-11-05 Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
US13/323,655 Abandoned US20120190567A1 (en) 2006-03-09 2011-12-12 Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
US14/690,182 Abandoned US20170328908A1 (en) 2006-03-09 2015-04-17 Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
US16/579,798 Active US11977076B2 (en) 2006-03-09 2019-09-23 Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells

Country Status (6)

Country Link
US (5) US20090061454A1 (fr)
EP (2) EP1999472A2 (fr)
JP (2) JP2009529329A (fr)
AU (1) AU2007223788B2 (fr)
CA (1) CA2645310A1 (fr)
WO (1) WO2007103541A2 (fr)

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090186951A1 (en) * 2007-09-19 2009-07-23 Brody Jerome S Identification of novel pathways for drug development for lung disease
US20090311692A1 (en) * 2003-11-12 2009-12-17 Brody Jerome S Isolation of nucleic acid from mouth epithelial cells
US20100035244A1 (en) * 2005-04-14 2010-02-11 The Trustees Of Boston University Diagnostic for lung disorders using class prediction
US20100055689A1 (en) * 2008-03-28 2010-03-04 Avrum Spira Multifactorial methods for detecting lung disorders
US20100113299A1 (en) * 2008-10-14 2010-05-06 Von Hoff Daniel D Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
US20100184046A1 (en) * 2008-11-12 2010-07-22 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
US20100304989A1 (en) * 2009-02-11 2010-12-02 Von Hoff Daniel D Molecular profiling of tumors
WO2010129708A3 (fr) * 2009-05-05 2011-01-13 Children's Hospital Medical Center Procédés et compositions liés à la régulation d'une différenciation de cellules caliciformes, production de mucus et sécrétion de mucus
WO2012149014A1 (fr) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer
WO2013032917A3 (fr) * 2011-08-29 2013-06-13 Cardiodx, Inc. Procédés et compositions pour la détermination du statut de fumeur
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
KR101495275B1 (ko) 2012-06-07 2015-02-24 한양대학교 산학협력단 폐암 진단 및 치료를 위한 표적 단백질
US9128101B2 (en) 2010-03-01 2015-09-08 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
WO2016011068A1 (fr) 2014-07-14 2016-01-21 Allegro Diagnostics Corp. Procédés pour évaluer le stade d'un cancer du poumon
US9469876B2 (en) 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
US20170152563A1 (en) * 2011-03-20 2017-06-01 Trustees Of Boston University Therapeutic agent for emphysema and copd
US10196687B2 (en) * 2007-06-01 2019-02-05 University Of North Carolina At Chapel Hill Molecular diagnosis and typing of lung cancer variants
US10288621B2 (en) * 2009-12-17 2019-05-14 Cornell University Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
US20190244677A1 (en) * 2016-09-14 2019-08-08 Philip Morris Products S.A. Systems, Methods, and Gene Signatures for Predicting the Biological Status of an Individual
US10526655B2 (en) 2013-03-14 2020-01-07 Veracyte, Inc. Methods for evaluating COPD status
KR20200078245A (ko) * 2018-12-21 2020-07-01 순천향대학교 산학협력단 공기오염물질 노출 여부 확인용 바이오마커 및 이를 이용한 공기오염물질 노출 확인 방법
CN111635944A (zh) * 2020-07-03 2020-09-08 南方医科大学南方医院 一种检测肝癌易感性位点rs73613962的特异性引物、试剂盒和PCR方法
US20200405225A1 (en) * 2017-06-02 2020-12-31 Veracyte, Inc. Methods and systems for identifying or monitoring lung disease
US10927417B2 (en) 2016-07-08 2021-02-23 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions
US11180539B2 (en) 2016-03-29 2021-11-23 Karydo Therapeutix, Inc. Pharmaceutical composition or food composition, and method for assessing effect of active ingredient in vivo
US11244760B2 (en) 2015-06-25 2022-02-08 Karydo Therapeutix, Inc. Prediction device based on inter-organ cross talk system
WO2022212283A1 (fr) * 2021-03-29 2022-10-06 Veracyte, Inc. Procédés et systèmes pour identifier un trouble pulmonaire
US11639527B2 (en) 2014-11-05 2023-05-02 Veracyte, Inc. Methods for nucleic acid sequencing
US11977076B2 (en) 2006-03-09 2024-05-07 Trustees Of Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12091701B2 (en) 2016-03-29 2024-09-17 Karydo Therapeutix, Inc. Screening method for candidate substances for active component to prevent or treat at least one disease selected from the group consisting of renal hypofunction, chronic kidney disease and kidney failure
US12110554B2 (en) 2009-05-07 2024-10-08 Veracyte, Inc. Methods for classification of tissue samples as positive or negative for cancer
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
US12305238B2 (en) 2008-11-17 2025-05-20 Veracyte, Inc. Methods for treatment of thyroid cancer
US12329759B2 (en) 2019-10-17 2025-06-17 Trustees Of Boston University Methods and compositions relating to lung function
US12577620B2 (en) 2016-05-12 2026-03-17 Trustees Of Boston University Nasal epithelium gene expression signature and classifier for the prediction of lung cancer

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8114593B2 (en) * 2008-03-12 2012-02-14 University Of Medicine And Dentistry Of New Jersey Cancer biomarker genes and gene products and methods for using the same
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
JP5854346B2 (ja) * 2010-07-21 2016-02-09 公立大学法人秋田県立大学 トランスクリプトーム解析方法、疾病判定方法、コンピュータプログラム、記憶媒体、及び解析装置
WO2013049152A2 (fr) * 2011-09-26 2013-04-04 Allegro Diagnostics Corp. Procédés pour évaluer le statut du cancer du poumon
WO2013177060A2 (fr) * 2012-05-20 2013-11-28 Trustees Of Boston University Procédés et systèmes pour surveiller, diagnostiquer et traiter la maladie pulmonaire obstructive chronique
CA2923335C (fr) 2013-09-13 2023-11-07 Philip Morris Products S.A. Systemes et procedes d'evaluation d'une perturbation du metabolisme xenobiotique
CN104198722A (zh) * 2014-08-11 2014-12-10 广东药学院 一种肺癌新肿瘤标志物gsta1及其筛选方法和应用
WO2016183414A1 (fr) * 2015-05-14 2016-11-17 The Arizona Board Of Regents On Behalf Of The University Of Arizona Systèmes et méthodes de caractérisation de maladies granulomateuses
KR20250073555A (ko) 2015-10-30 2025-05-27 이그잭트 사이언시즈 코포레이션 복합 증폭 검출 분석 및 혈장으로부터 dna의 분리 및 검출 방법
CN116064796A (zh) 2016-05-05 2023-05-05 精密科学公司 通过分析甲基化dna来检测肺肿瘤
JP2022546504A (ja) * 2019-08-27 2022-11-04 エグザクト サイエンシーズ コーポレーション 肺新生物形成を有する疑いのある対象におけるメチル化されたｄｎａ、ｒｎａ、及びタンパク質の特性決定
AU2021409465A1 (en) 2020-12-21 2023-08-03 Freenome Holdings, Inc. Markers for the early detection of colon cell proliferative disorders
EP4623092A1 (fr) * 2022-11-21 2025-10-01 Merck Sharp & Dohme LLC Signatures basées sur l'expression génique dérivée d'une tumeur à l'échelle du génome associées à un pronostic médiocre pour des patients atteints d'un mélanome avec une maladie à un stade précoce
WO2025028453A1 (fr) * 2023-07-31 2025-02-06 国立大学法人大阪大学 Biomarqueur du cancer du poumon
WO2025109033A1 (fr) 2023-11-21 2025-05-30 Oncoswab Gmbh Procédé pour identifier si un sujet présente un risque de développer un cancer du poumon

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4800896A (en) * 1985-11-08 1989-01-31 Jalowayski Alfredo A Cell sample collector probe
US20030104499A1 (en) * 2001-03-12 2003-06-05 Monogen, Inc. Cell-based detection and differentiation of lung cancer
US20040005297A1 (en) * 2002-07-08 2004-01-08 Connelly Patrick R. Biological scaffold
US20040009489A1 (en) * 2001-09-28 2004-01-15 Golub Todd R. Classification of lung carcinomas using gene expression analysis
US20040063120A1 (en) * 2002-07-10 2004-04-01 The Regents Of The University Of Michigan Expression profile of lung cancer
US6746846B1 (en) * 1999-06-30 2004-06-08 Corixa Corporation Methods for diagnosing lung cancer
US20040241725A1 (en) * 2003-03-25 2004-12-02 Wenming Xiao Lung cancer detection
US20050266409A1 (en) * 2003-02-04 2005-12-01 Wyeth Compositions and methods for diagnosing, preventing, and treating cancers
US20060127928A1 (en) * 2004-12-10 2006-06-15 Bacus Sarah S Targeted therapy marker panels
US20060154278A1 (en) * 2003-06-10 2006-07-13 The Trustees Of Boston University Detection methods for disorders of the lung
US20070148650A1 (en) * 2003-11-12 2007-06-28 Trustees Of Boston University Isolation of nucleic acid from mouth epithelial cells
US20090186951A1 (en) * 2007-09-19 2009-07-23 Brody Jerome S Identification of novel pathways for drug development for lung disease
US20100035244A1 (en) * 2005-04-14 2010-02-11 The Trustees Of Boston University Diagnostic for lung disorders using class prediction
US20100055689A1 (en) * 2008-03-28 2010-03-04 Avrum Spira Multifactorial methods for detecting lung disorders

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1359801A (en) 1920-03-03 1920-11-23 Goldner Joe Combination mattress and pillow
US3640268A (en) * 1965-10-23 1972-02-08 Hugh J Davis Method and device for biopsy specimen collecting and handling
US4437975A (en) 1977-07-20 1984-03-20 Mobil Oil Corporation Manufacture of lube base stock oil
US4632901A (en) 1984-05-11 1986-12-30 Hybritech Incorporated Method and apparatus for immunoassays
US4641662A (en) * 1984-09-28 1987-02-10 Jaicks John R Endocervical curette system
US5242794A (en) 1984-12-13 1993-09-07 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5333675C1 (en) 1986-02-25 2001-05-01 Perkin Elmer Corp Apparatus and method for performing automated amplification of nucleic acid sequences and assays using heating and cooling steps
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
IL86724A (en) 1987-06-19 1995-01-24 Siska Diagnostics Inc Methods and kits for amplification and testing of nucleic acid sequences
CA1340843C (fr) 1987-07-31 1999-12-07 J. Lawrence Burg Amplification selective de sequences polynucleotidiques cibles
JP2650159B2 (ja) 1988-02-24 1997-09-03 アクゾ・ノベル・エヌ・ベー 核酸増幅方法
CA1340807C (fr) 1988-02-24 1999-11-02 Lawrence T. Malek Procede d'amplification d'une sequence d'acide nucleique
US4988617A (en) 1988-03-25 1991-01-29 California Institute Of Technology Method of detecting a nucleotide change in nucleic acids
WO1990006995A1 (fr) 1988-12-16 1990-06-28 Siska Diagnostics, Inc. Systeme auto-entretenu de replication sequentielle
US5856092A (en) 1989-02-13 1999-01-05 Geneco Pty Ltd Detection of a nucleic acid sequence or a change therein
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6346413B1 (en) 1989-06-07 2002-02-12 Affymetrix, Inc. Polymer arrays
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5871928A (en) 1989-06-07 1999-02-16 Fodor; Stephen P. A. Methods for nucleic acid analysis
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5242974A (en) 1991-11-22 1993-09-07 Affymax Technologies N.V. Polymer reversal on solid surfaces
US5527681A (en) 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US6309822B1 (en) 1989-06-07 2001-10-30 Affymetrix, Inc. Method for comparing copy number of nucleic acid sequences
US5252743A (en) 1989-11-13 1993-10-12 Affymax Technologies N.V. Spatially-addressable immobilization of anti-ligands on surfaces
US6013431A (en) 1990-02-16 2000-01-11 Molecular Tool, Inc. Method for determining specific nucleotide variations by primer extension in the presence of mixture of labeled nucleotides and terminators
US5494810A (en) 1990-05-03 1996-02-27 Cornell Research Foundation, Inc. Thermostable ligase-mediated DNA amplifications system for the detection of genetic disease
EP0561796B1 (fr) 1990-08-24 1997-12-29 The University Of Tennessee Research Corporation Technique de l'emprunte digitale des adn utilisee en vue de leur amplification
WO1992007095A1 (fr) 1990-10-15 1992-04-30 Stratagene Procede de reaction en chaine de polymerase arbitrairement amorcee destine a produire une empreinte genetique de genomes
US5726060A (en) * 1991-09-17 1998-03-10 Bridges; Michael Anthony Method for culturing mammalian respiratory epithelial cells
US5550215A (en) 1991-11-22 1996-08-27 Holmes; Christopher P. Polymer reversal on solid surfaces
US5677195A (en) 1991-11-22 1997-10-14 Affymax Technologies N.V. Combinatorial strategies for polymer synthesis
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5324633A (en) 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5541061A (en) 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
US5422273A (en) * 1993-03-23 1995-06-06 Baal Medical Products, Inc. Cell collection apparatus
US5491074A (en) 1993-04-01 1996-02-13 Affymax Technologies Nv Association peptides
US5639606A (en) 1993-04-06 1997-06-17 The University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5643765A (en) 1993-04-06 1997-07-01 University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5876978A (en) 1993-04-06 1999-03-02 Medical College Of Ohio Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5477863A (en) * 1993-04-14 1995-12-26 Grant; Michael A. Collection kit with a sample collector
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6045996A (en) 1993-10-26 2000-04-04 Affymetrix, Inc. Hybridization assays on oligonucleotide arrays
US5440942A (en) * 1994-02-02 1995-08-15 Hubbard; Stephen H. Biological sample collecting and holding device
US5631734A (en) 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
US6090555A (en) 1997-12-11 2000-07-18 Affymetrix, Inc. Scanned image alignment systems and methods
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
WO1995030774A1 (fr) 1994-05-05 1995-11-16 Beckman Instruments, Inc. Groupements repetes d'oligonucleotides
US5571639A (en) 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
US5959098A (en) 1996-04-17 1999-09-28 Affymetrix, Inc. Substrate preparation process
US5599695A (en) 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US5795782A (en) 1995-03-17 1998-08-18 President & Fellows Of Harvard College Characterization of individual polymer molecules based on monomer-interface interactions
US5624711A (en) 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5968740A (en) 1995-07-24 1999-10-19 Affymetrix, Inc. Method of Identifying a Base in a Nucleic Acid
US5733729A (en) 1995-09-14 1998-03-31 Affymetrix, Inc. Computer-aided probability base calling for arrays of nucleic acid probes on chips
US6147205A (en) 1995-12-15 2000-11-14 Affymetrix, Inc. Photocleavable protecting groups and methods for their use
US6114122A (en) 1996-03-26 2000-09-05 Affymetrix, Inc. Fluidics station with a mounting system and method of using
JP2000512744A (ja) 1996-05-16 2000-09-26 アフィメトリックス，インコーポレイテッド 標識材料を検出するシステムおよび方法
JP3402972B2 (ja) 1996-11-14 2003-05-06 東京エレクトロン株式会社 半導体装置の製造方法
WO1999005574A1 (fr) 1997-07-25 1999-02-04 Affymetrix, Inc. PROCEDE ET SYSTEME D'OBTENTION D'UNE BASE DE DONNEES DE CONCEPTION DE PUCES A ENSEMBLES DE SONDES$i()
EP1019536B1 (fr) 1997-08-15 2004-10-20 Affymetrix, Inc. Detection des polymorphismes a l'aide de la theorie des grappes
AU1287799A (en) 1997-10-31 1999-05-24 Affymetrix, Inc. Expression profiles in adult and fetal organs
US6013449A (en) 1997-11-26 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Probe-based analysis of heterozygous mutations using two-color labelling
US6269846B1 (en) 1998-01-13 2001-08-07 Genetic Microsystems, Inc. Depositing fluid specimens on substrates, resulting ordered arrays, techniques for deposition of arrays
US6428752B1 (en) 1998-05-14 2002-08-06 Affymetrix, Inc. Cleaning deposit devices that form microarrays and the like
US6201639B1 (en) 1998-03-20 2001-03-13 James W. Overbeck Wide field of view and high speed scanning microscopy
US6185030B1 (en) 1998-03-20 2001-02-06 James W. Overbeck Wide field of view and high speed scanning microscopy
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US5936324A (en) 1998-03-30 1999-08-10 Genetic Microsystems Inc. Moving magnet scanner
US6085907A (en) * 1998-05-08 2000-07-11 Institute Of Legal Medicine, University Of Bern Foldable cardboard box for contact-free drying and long-term storage of biological evidence recovered on cotton swabs and forensic evidence collection kit including same
CA2328138A1 (fr) 1998-05-21 1999-11-25 Diadexus Llc Technique de diagnostic, de suivi et de stadification du cancer du poumon
US6204375B1 (en) 1998-07-31 2001-03-20 Ambion, Inc. Methods and reagents for preserving RNA in cell and tissue samples
US6185561B1 (en) 1998-09-17 2001-02-06 Affymetrix, Inc. Method and apparatus for providing and expression data mining database
US6262216B1 (en) 1998-10-13 2001-07-17 Affymetrix, Inc. Functionalized silicon compounds and methods for their synthesis and use
EP1124990B1 (fr) 1998-10-27 2006-01-18 Affymetrix, Inc. Gestion de la complexite et analyse d'adn genomique
WO2000035473A2 (fr) 1998-12-18 2000-06-22 Scios Inc. Methodes de detection et d'utilisation de genes exprimes de façon differentielle dans des maladies
US20040241728A1 (en) * 1999-01-06 2004-12-02 Chondrogene Limited Method for the detection of lung disease related gene transcripts in blood
US6177248B1 (en) 1999-02-24 2001-01-23 Affymetrix, Inc. Downstream genes of tumor suppressor WT1
EP1165839A2 (fr) 1999-03-26 2002-01-02 Whitehead Institute For Biomedical Research Reseaux universels
US6300070B1 (en) 1999-06-04 2001-10-09 Mosaic Technologies, Inc. Solid phase methods for amplifying multiple nucleic acids
US6218803B1 (en) 1999-06-04 2001-04-17 Genetic Microsystems, Inc. Position sensing with variable capacitance transducers
US6667154B1 (en) * 1999-06-30 2003-12-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CN1379641A (zh) 1999-10-18 2002-11-13 丹尼斯·马歇尔－弗雷泽 取样装置
US6386749B1 (en) 2000-06-26 2002-05-14 Affymetrix, Inc. Systems and methods for heating and mixing fluids
US6383804B1 (en) 2000-07-13 2002-05-07 International Bioproducts, Inc. Sampling device with snap-off head and method of use
US6797471B2 (en) 2000-08-04 2004-09-28 Board Of Regents, The University Of Texas System Detection and diagnosis of smoking related cancers
WO2002040673A2 (fr) * 2000-11-20 2002-05-23 Diadexus, Inc. Compositions et methodes relatives a des genes et des proteines specifiques aux poumons
AU2002236507A1 (en) 2000-11-29 2002-06-11 Cangen International Dap-kinase and hoxa9, two human genes associated with genesis, progression, and aggressiveness of non-small cell lung cancer
US6391592B1 (en) 2000-12-14 2002-05-21 Affymetrix, Inc. Blocker-aided target amplification of nucleic acids
US6972181B2 (en) 2001-01-12 2005-12-06 Mount Sinai School Of Medicine Of New York University Differential diagnosis of cancer and other conditions based on expression of p63
WO2003040325A2 (fr) 2001-02-01 2003-05-15 Curagen Corporation Nouvelles proteines et acides nucleiques codant ces proteines
WO2002072866A2 (fr) 2001-03-14 2002-09-19 Medical College Of Ohio Procede de mesure quantitative de l'expression genique permettant d'identifier des individus susceptibles de carcinome bronchogenique
JP2005527180A (ja) 2001-04-18 2005-09-15 プロテイン デザイン ラブス， インコーポレイテッド 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法
US6494845B2 (en) 2001-05-04 2002-12-17 Oralscan Laboratories, Inc. Retractable brush for use with endoscope for brush biopsy
CA2456334A1 (fr) 2001-08-16 2003-02-27 The United States Of America As Represented By The Secretary Department Of Health And Human Services Caracteristiques moleculaires du cancer du poumon non a petites cellules
EP1520032A4 (fr) 2001-11-02 2007-07-18 Pfizer Prod Inc Moyens therapeutiques et diagnostiques applicables au cancer du poumon
US7141372B2 (en) 2002-01-18 2006-11-28 Health Research Incorporated Universal RT-coupled PCR method for the specific amplification of mRNA
US20040005294A1 (en) 2002-02-25 2004-01-08 Ho-Young Lee IGFBP-3 in the diagnosis and treatment of cancer
JP2006506945A (ja) 2002-03-28 2006-03-02 メディカル・カレッジ・オブ・オハイオ 遺伝子発現プロフィールを使用する非小細胞肺癌の診断および処置のための方法および組成物
US20030186248A1 (en) 2002-03-29 2003-10-02 Erlander Mark G. Interpreting cytological specimens via molecular histological signatures
DE10219117C1 (de) 2002-04-29 2003-10-30 Adnagen Ag Verfahren zur Stabilisierung von RNS und Verwendungen von Stabilisierungspuffern
AU2003293310B2 (en) 2002-09-30 2010-04-01 Bayer Intellectual Property Gmbh Fused azole-pyrimidine derivatives
WO2004091511A2 (fr) 2003-04-10 2004-10-28 Genzyme Corporation Compositions et methodes de diagnostic et de traitement du cancer du poumon
US20070105105A1 (en) 2003-05-23 2007-05-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
WO2004111197A2 (fr) 2003-06-10 2004-12-23 Trustees Of Boston University Signatures d'expression genetique, procedes et compositions permettant de diagnostiquer des troubles des poumons
EP1753873A4 (fr) 2004-03-05 2008-11-05 Ohio Med College Procedes et compositions pour l'evaluation d'acides nucleiques et d'alleles
WO2006056080A1 (fr) 2004-11-29 2006-06-01 Diagnocure Inc. Gene gpx2, cible specifique et sensible pour le diagnostic, le pronostic et/ou la theranose concernant le cancer du poumon
DE602005025685D1 (de) 2004-12-03 2011-02-10 Schering Corp Biologische marker zur vorauswahl von patienten für die anti-igf1r-therapie
WO2006079033A2 (fr) 2005-01-21 2006-07-27 Gene Express, Inc. Procedes et compositions pour evaluer des acides nucleiques
JP2009506778A (ja) 2005-09-02 2009-02-19 ザ・ユニバーシティ・オブ・トレド 生物学的状態の診断および／または治療に有用なバイオマーカを同定する方法および組成物
EP1999472A2 (fr) 2006-03-09 2008-12-10 The Trustees Of Boston University Méthodes de diagnostic et de pronostic pour troubles des poumons utilisant des profils d'expression de gènes de cellules épithéliales nasales
US20230235401A1 (en) 2007-09-19 2023-07-27 Trustees Of Boston University Biomarkers for smoke exposure
US20090246779A1 (en) 2008-02-15 2009-10-01 University Of Washington Increasing genomic instability during premalignant neoplastic progression revealed through high resolution array-cgh
US9068974B2 (en) 2008-11-08 2015-06-30 The Wistar Institute Of Anatomy And Biology Biomarkers in peripheral blood mononuclear cells for diagnosing or detecting lung cancers
CN102725632A (zh) 2009-08-28 2012-10-10 奥斯瑞根公司 肺病的miRNA生物标志物
WO2012094744A1 (fr) 2011-01-11 2012-07-19 University Health Network Signature prognostique d'un carcinome épidermoïde de la cavité buccale
US20120288860A1 (en) 2011-05-12 2012-11-15 George Mason University Differential gene expression for detecting and/or differentiating lung disease
WO2013033640A1 (fr) 2011-09-01 2013-03-07 Allegro Diagnostics Corp. Procédés et compositions pour la détection du cancer sur la base de profils d'expression de miarn
WO2013049152A2 (fr) 2011-09-26 2013-04-04 Allegro Diagnostics Corp. Procédés pour évaluer le statut du cancer du poumon
AU2013229762A1 (en) 2012-03-09 2014-09-25 Caris Life Sciences Switzerland Holdings Gmbh Biomarker compositions and methods
US20150088430A1 (en) 2012-04-26 2015-03-26 Allegro Diagnostics Corp Methods for evaluating lung cancer status
WO2013177060A2 (fr) 2012-05-20 2013-11-28 Trustees Of Boston University Procédés et systèmes pour surveiller, diagnostiquer et traiter la maladie pulmonaire obstructive chronique
WO2014186036A1 (fr) 2013-03-14 2014-11-20 Allegro Diagnostics Corp. Procédés d'évaluation de l'état d'une maladie pulmonaire obstructive chronique (copd)
CN109504768A (zh) 2013-03-15 2019-03-22 威拉赛特公司 用于诊断肺病的生物标记物及其使用方法
CA2954169A1 (fr) 2014-07-14 2016-01-21 Allegro Diagnostics Corp. Procedes pour evaluer le stade d'un cancer du poumon
EP4180531A3 (fr) 2016-05-12 2023-08-23 Trustees of Boston University Signature d'expression génique de l'épithélium nasal et classificateur pour la prédiction du cancer du poumon
WO2018009915A1 (fr) 2016-07-08 2018-01-11 Trustees Of Boston University Biomarqueur basé sur l'expression génique pour la détection et la surveillance de lésions précancéreuses bronchiques
AU2017324949B2 (en) 2016-09-07 2024-05-23 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4800896A (en) * 1985-11-08 1989-01-31 Jalowayski Alfredo A Cell sample collector probe
US6746846B1 (en) * 1999-06-30 2004-06-08 Corixa Corporation Methods for diagnosing lung cancer
US20030104499A1 (en) * 2001-03-12 2003-06-05 Monogen, Inc. Cell-based detection and differentiation of lung cancer
US20040009489A1 (en) * 2001-09-28 2004-01-15 Golub Todd R. Classification of lung carcinomas using gene expression analysis
US20040005297A1 (en) * 2002-07-08 2004-01-08 Connelly Patrick R. Biological scaffold
US20040063120A1 (en) * 2002-07-10 2004-04-01 The Regents Of The University Of Michigan Expression profile of lung cancer
US20050266409A1 (en) * 2003-02-04 2005-12-01 Wyeth Compositions and methods for diagnosing, preventing, and treating cancers
US20040241725A1 (en) * 2003-03-25 2004-12-02 Wenming Xiao Lung cancer detection
US20060154278A1 (en) * 2003-06-10 2006-07-13 The Trustees Of Boston University Detection methods for disorders of the lung
US20070148650A1 (en) * 2003-11-12 2007-06-28 Trustees Of Boston University Isolation of nucleic acid from mouth epithelial cells
US20090311692A1 (en) * 2003-11-12 2009-12-17 Brody Jerome S Isolation of nucleic acid from mouth epithelial cells
US20060127928A1 (en) * 2004-12-10 2006-06-15 Bacus Sarah S Targeted therapy marker panels
US20100035244A1 (en) * 2005-04-14 2010-02-11 The Trustees Of Boston University Diagnostic for lung disorders using class prediction
US20090186951A1 (en) * 2007-09-19 2009-07-23 Brody Jerome S Identification of novel pathways for drug development for lung disease
US20100055689A1 (en) * 2008-03-28 2010-03-04 Avrum Spira Multifactorial methods for detecting lung disorders

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090311692A1 (en) * 2003-11-12 2009-12-17 Brody Jerome S Isolation of nucleic acid from mouth epithelial cells
US20100035244A1 (en) * 2005-04-14 2010-02-11 The Trustees Of Boston University Diagnostic for lung disorders using class prediction
US10808285B2 (en) 2005-04-14 2020-10-20 Trustees Of Boston University Diagnostic for lung disorders using class prediction
US9920374B2 (en) 2005-04-14 2018-03-20 Trustees Of Boston University Diagnostic for lung disorders using class prediction
US11977076B2 (en) 2006-03-09 2024-05-07 Trustees Of Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
US10196687B2 (en) * 2007-06-01 2019-02-05 University Of North Carolina At Chapel Hill Molecular diagnosis and typing of lung cancer variants
US20090186951A1 (en) * 2007-09-19 2009-07-23 Brody Jerome S Identification of novel pathways for drug development for lung disease
US10570454B2 (en) 2007-09-19 2020-02-25 Trustees Of Boston University Methods of identifying individuals at increased risk of lung cancer
US20100055689A1 (en) * 2008-03-28 2010-03-04 Avrum Spira Multifactorial methods for detecting lung disorders
US20100113299A1 (en) * 2008-10-14 2010-05-06 Von Hoff Daniel D Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
US20100203529A1 (en) * 2008-11-12 2010-08-12 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
US7897356B2 (en) 2008-11-12 2011-03-01 Caris Life Sciences Methods and systems of using exosomes for determining phenotypes
US20100184046A1 (en) * 2008-11-12 2010-07-22 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
US12305238B2 (en) 2008-11-17 2025-05-20 Veracyte, Inc. Methods for treatment of thyroid cancer
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US20100304989A1 (en) * 2009-02-11 2010-12-02 Von Hoff Daniel D Molecular profiling of tumors
WO2010129708A3 (fr) * 2009-05-05 2011-01-13 Children's Hospital Medical Center Procédés et compositions liés à la régulation d'une différenciation de cellules caliciformes, production de mucus et sécrétion de mucus
US12110554B2 (en) 2009-05-07 2024-10-08 Veracyte, Inc. Methods for classification of tissue samples as positive or negative for cancer
US12297503B2 (en) 2009-05-07 2025-05-13 Veracyte, Inc. Methods for classification of tissue samples as positive or negative for cancer
US10288621B2 (en) * 2009-12-17 2019-05-14 Cornell University Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
US11782063B2 (en) 2009-12-17 2023-10-10 Cornell University Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
US9128101B2 (en) 2010-03-01 2015-09-08 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
US9469876B2 (en) 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
US20170152563A1 (en) * 2011-03-20 2017-06-01 Trustees Of Boston University Therapeutic agent for emphysema and copd
US10233498B2 (en) * 2011-03-20 2019-03-19 Trustees Of Boston University Therapeutic agent for emphysema and COPD
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
WO2012149014A1 (fr) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer
WO2013032917A3 (fr) * 2011-08-29 2013-06-13 Cardiodx, Inc. Procédés et compositions pour la détermination du statut de fumeur
CN103890193A (zh) * 2011-08-29 2014-06-25 心脏Dx公司 用于确定吸烟状态的方法和组合物
EP2751290A4 (fr) * 2011-08-29 2015-07-15 Cardiodx Inc Procédés et compositions pour la détermination du statut de fumeur
KR101495275B1 (ko) 2012-06-07 2015-02-24 한양대학교 산학협력단 폐암 진단 및 치료를 위한 표적 단백질
US10526655B2 (en) 2013-03-14 2020-01-07 Veracyte, Inc. Methods for evaluating COPD status
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
WO2016011068A1 (fr) 2014-07-14 2016-01-21 Allegro Diagnostics Corp. Procédés pour évaluer le stade d'un cancer du poumon
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
EP3916110A1 (fr) 2014-07-14 2021-12-01 Veracyte, Inc. Procédés pour évaluer le stade d'un cancer du poumon
US11639527B2 (en) 2014-11-05 2023-05-02 Veracyte, Inc. Methods for nucleic acid sequencing
US12534763B2 (en) 2014-11-05 2026-01-27 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis
US11244760B2 (en) 2015-06-25 2022-02-08 Karydo Therapeutix, Inc. Prediction device based on inter-organ cross talk system
US12091701B2 (en) 2016-03-29 2024-09-17 Karydo Therapeutix, Inc. Screening method for candidate substances for active component to prevent or treat at least one disease selected from the group consisting of renal hypofunction, chronic kidney disease and kidney failure
US11180539B2 (en) 2016-03-29 2021-11-23 Karydo Therapeutix, Inc. Pharmaceutical composition or food composition, and method for assessing effect of active ingredient in vivo
US12577620B2 (en) 2016-05-12 2026-03-17 Trustees Of Boston University Nasal epithelium gene expression signature and classifier for the prediction of lung cancer
US10927417B2 (en) 2016-07-08 2021-02-23 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions
US20190244677A1 (en) * 2016-09-14 2019-08-08 Philip Morris Products S.A. Systems, Methods, and Gene Signatures for Predicting the Biological Status of an Individual
US20200405225A1 (en) * 2017-06-02 2020-12-31 Veracyte, Inc. Methods and systems for identifying or monitoring lung disease
KR102130032B1 (ko) * 2018-12-21 2020-07-03 순천향대학교 산학협력단 공기오염물질 노출 여부 확인용 바이오마커 및 이를 이용한 공기오염물질 노출 확인 방법
KR20200078245A (ko) * 2018-12-21 2020-07-01 순천향대학교 산학협력단 공기오염물질 노출 여부 확인용 바이오마커 및 이를 이용한 공기오염물질 노출 확인 방법
US12329759B2 (en) 2019-10-17 2025-06-17 Trustees Of Boston University Methods and compositions relating to lung function
CN111635944A (zh) * 2020-07-03 2020-09-08 南方医科大学南方医院 一种检测肝癌易感性位点rs73613962的特异性引物、试剂盒和PCR方法
WO2022212283A1 (fr) * 2021-03-29 2022-10-06 Veracyte, Inc. Procédés et systèmes pour identifier un trouble pulmonaire

Also Published As

Publication number Publication date
WO2007103541A2 (fr) 2007-09-13
EP1999472A2 (fr) 2008-12-10
US20200096513A1 (en) 2020-03-26
WO2007103541A3 (fr) 2008-01-10
JP2013126427A (ja) 2013-06-27
US20170328908A1 (en) 2017-11-16
AU2007223788A1 (en) 2007-09-13
US11977076B2 (en) 2024-05-07
AU2007223788B2 (en) 2012-11-29
EP2605018A1 (fr) 2013-06-19
JP2009529329A (ja) 2009-08-20
CA2645310A1 (fr) 2007-09-13
US20120190567A1 (en) 2012-07-26
US20110217717A1 (en) 2011-09-08

Similar Documents

Publication Publication Date Title
US11977076B2 (en) Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
US20200248274A1 (en) Diagnostic for lung disorders using class prediction
US10808285B2 (en) Diagnostic for lung disorders using class prediction
US20200405225A1 (en) Methods and systems for identifying or monitoring lung disease
Kantola et al. Prognostic factors in tongue cancer–relative importance of demographic, clinical and histopathological factors
Borczuk et al. Molecular signatures in biopsy specimens of lung cancer
Geisler et al. p16 and p53 Protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer
EP2327795B1 (fr) Méthodes de détection de troubles poulmonaires
JP6696974B2 (ja) 痰由来細胞のｄｎａメチル化表現型決定による早期肺癌検出方法
US20200123613A1 (en) Compositions and methods for diagnosing lung cancers using gene expression profiles
BR112021003095A2 (pt) métodos relacionados à gravidade e progressão de lesão pré-maligna bronquial
EP2909345A1 (fr) Compositions et procédés de détection d'adénomes/polypes striés sessiles
US20020004206A1 (en) Methods of screening for disease
Yu et al. Expression of cyclin genes in human gastric cancer and in first degree relatives
Kennedy et al. Using molecular markers in sputum for the early detection of lung cancer: a review
Mohammed et al. Evaluation of Methylation Panel in the Promoter Region of p16INK4a, RASSF1A, and MGMT as a Biomarker in Sputum for Lung Cancer
CN113355412B (zh) 用于辅助诊断癌症的甲基化标志物及试剂盒
JP2018139537A (ja) 食道がんのリンパ節転移可能性のデータ取得方法
Nishii et al. Discrepancy Between Clinical Diagnosis and Whole-exome Sequencing-based Clonality Analysis of Synchronous Multiple Oral Cancers
HK1237001B (zh) 通过唾液来源细胞的dna甲基化表型分型进行早期肺癌检测

Legal Events

Date Code Title Description
AS Assignment

Owner name: THE TRUSTEES OF BOSTON UNIVERSITY, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRODY, JEROME S;SPIRA, AVRUM;BERMAN, JEFFREY S;AND OTHERS;REEL/FRAME:019919/0246;SIGNING DATES FROM 20070425 TO 20070905

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: GALA THERAPEUTICS BVBA - SPRL, BELGIUM

Free format text: SECURITY AGREEMENT;ASSIGNOR:ALLEGRO DIAGNOSTICS CORP.;REEL/FRAME:031531/0277

Effective date: 20131030

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT, MARYLAND

Free format text: LICENSE;ASSIGNOR:BOSTON UNIVERSITY MEDICAL CAMPUS;REEL/FRAME:069246/0629

Effective date: 20230629